1
|
Taba G, Ceccato V, Fernandes O, Michel S, Darrigues L, Girard N, Gauroy E, Pauly L, Gaillard T, Reyal F, Hotton J. Impact of ERAS in breast reconstruction with a latissimus dorsi flap, compared to conventional management. J Plast Reconstr Aesthet Surg 2023; 85:202-209. [PMID: 37524032 DOI: 10.1016/j.bjps.2023.06.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 06/12/2023] [Accepted: 06/29/2023] [Indexed: 08/02/2023]
Abstract
BACKGROUND Enhanced recovery after surgery (ERAS) programs are associated with improved management, reduced hospital stays, and lower complication rates. OBJECTIVE To evaluate the impact of ERAS on mean length of stay (LOS) and postoperative morbidity in breast reconstruction with latissimus dorsi flap (LDF) compared with conventional recovery program. PATIENTS AND METHOD All patients operated by LDF between December 2014 and October 2020: those managed before April 2018, when the ERAS protocol was introduced, were included in the "no ERAS" group, and beyond in the "ERAS" group. RESULTS Out of 193 patients, 129 were included in the "ERAS" group and 64 in the "no ERAS" group. There was a significant difference between the two groups in LOS (4.2 ± 1.5 days in the "ERAS" group vs. 5.4 ± 1.9 days in the "no ERAS" group; p < 0.001), high-grade complications at 30 days (9.3% in the "ERAS" group vs. 25% in the "no ERAS" group; p = 0.01), reintervention rate (13.9% vs. 26.6%, respectively; p = 0.02), and 30-day rehospitalization rate (6.2% in the "ERAS" group vs. 15.6% in the "no ERAS" group; p = 0.03). CONCLUSION The ERAS protocol has a positive impact on breast reconstruction with LDF without generating additional adverse effects. These results support the democratization of these programs for breast reconstruction surgery.
Collapse
Affiliation(s)
- G Taba
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - V Ceccato
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - O Fernandes
- Department of Anesthesia, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - S Michel
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - L Darrigues
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - N Girard
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - E Gauroy
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - L Pauly
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - T Gaillard
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - F Reyal
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France
| | - J Hotton
- Department of Surgical Oncology, Institut Godinot, Rue du Général Koenig, 51100 Reims, France.
| |
Collapse
|
2
|
Elmahjoubi A, Shoker MB, Pagès O, Torres VJB, Polian A, Postnikov AV, Bellin C, Béneut K, Gardiennet C, Kervern G, En Naciri A, Broch L, Hajj Hussein R, Itié JP, Nataf L, Ravy S, Franchetti P, Diliberto S, Michel S, Abouais A, Strzałkowski K. Vibrational-mechanical properties of the highly-mismatched Cd 1-xBe xTe semiconductor alloy: experiment and ab initio calculations. Sci Rep 2023; 13:14571. [PMID: 37666909 PMCID: PMC10477277 DOI: 10.1038/s41598-023-39248-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Accepted: 07/21/2023] [Indexed: 09/06/2023] Open
Abstract
The emerging CdTe-BeTe semiconductor alloy that exhibits a dramatic mismatch in bond covalency and bond stiffness clarifying its vibrational-mechanical properties is used as a benchmark to test the limits of the percolation model (PM) worked out to explain the complex Raman spectra of the related but less contrasted Zn1-xBex-chalcogenides. The test is done by way of experiment ([Formula: see text]), combining Raman scattering with X-ray diffraction at high pressure, and ab initio calculations ([Formula: see text] ~ 0-0.5; [Formula: see text]~1). The (macroscopic) bulk modulus [Formula: see text] drops below the CdTe value on minor Be incorporation, at variance with a linear [Formula: see text] versus [Formula: see text] increase predicted ab initio, thus hinting at large anharmonic effects in the real crystal. Yet, no anomaly occurs at the (microscopic) bond scale as the regular bimodal PM-type Raman signal predicted ab initio for Be-Te in minority ([Formula: see text]~0, 0.5) is barely detected experimentally. At large Be content ([Formula: see text]~1), the same bimodal signal relaxes all the way down to inversion, an unprecedented case. However, specific pressure dependencies of the regular ([Formula: see text]~0, 0.5) and inverted ([Formula: see text]~1) Be-Te Raman doublets are in line with the predictions of the PM. Hence, the PM applies as such to Cd1-xBexTe without further refinement, albeit in a "relaxed" form. This enhances the model's validity as a generic descriptor of phonons in alloys.
Collapse
Affiliation(s)
- A Elmahjoubi
- LCP-A2MC, UR 4632, Université de Lorraine, 57000, Metz, France
| | - M B Shoker
- LCP-A2MC, UR 4632, Université de Lorraine, 57000, Metz, France
- Department of Physics and Materials Science, University of Luxembourg, 41 rue du Brill, 4422, Belvaux, Luxembourg
| | - O Pagès
- LCP-A2MC, UR 4632, Université de Lorraine, 57000, Metz, France.
| | - V J B Torres
- Departamento de Fisica and i3N, Universidade de Aveiro, 3810 - 193, Aveiro, Portugal
| | - A Polian
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Sorbonne Université - UMR CNRS 7590, 75005, Paris, France
- Synchrotron SOLEIL, L'Orme des Merisiers Saint-Aubin, BP 48, 91192, Gif-sur-Yvette Cedex, France
| | - A V Postnikov
- LCP-A2MC, UR 4632, Université de Lorraine, 57000, Metz, France
| | - C Bellin
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Sorbonne Université - UMR CNRS 7590, 75005, Paris, France
| | - K Béneut
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Sorbonne Université - UMR CNRS 7590, 75005, Paris, France
| | - C Gardiennet
- Laboratoire de Cristallographie, Résonance Magnétique et Modélisations, CRM2, UMR 7036, Université de Lorraine, 54506, Vandoeuvre-lès-Nancy, France
| | - G Kervern
- Laboratoire de Cristallographie, Résonance Magnétique et Modélisations, CRM2, UMR 7036, Université de Lorraine, 54506, Vandoeuvre-lès-Nancy, France
| | - A En Naciri
- LCP-A2MC, UR 4632, Université de Lorraine, 57000, Metz, France
| | - L Broch
- LCP-A2MC, UR 4632, Université de Lorraine, 57000, Metz, France
| | - R Hajj Hussein
- LCP-A2MC, UR 4632, Université de Lorraine, 57000, Metz, France
| | - J-P Itié
- Synchrotron SOLEIL, L'Orme des Merisiers Saint-Aubin, BP 48, 91192, Gif-sur-Yvette Cedex, France
| | - L Nataf
- Synchrotron SOLEIL, L'Orme des Merisiers Saint-Aubin, BP 48, 91192, Gif-sur-Yvette Cedex, France
| | - S Ravy
- Synchrotron SOLEIL, L'Orme des Merisiers Saint-Aubin, BP 48, 91192, Gif-sur-Yvette Cedex, France
| | - P Franchetti
- LCP-A2MC, UR 4632, Université de Lorraine, 57000, Metz, France
| | - S Diliberto
- IJL, CNRS, Université de Lorraine, 57000, Metz, France
| | - S Michel
- IJL, CNRS, Université de Lorraine, 57000, Metz, France
| | - A Abouais
- Faculty of Physics, Astronomy and Informatics, Institute of Physics, Nicolaus Copernicus University in Toruń, Ul. Grudziądzka 5, 87-100, Toruń, Poland
- Engineering Science for Energy Lab, National School of Applied Sciences, Chouaib Doukkali University of El Jadida, El Jadida, Morocco
| | - K Strzałkowski
- Faculty of Physics, Astronomy and Informatics, Institute of Physics, Nicolaus Copernicus University in Toruń, Ul. Grudziądzka 5, 87-100, Toruń, Poland
| |
Collapse
|
3
|
Caré W, Grenet G, Schmitt C, Michel S, Langrand J, Le Roux G, Vodovar D. [Adverse effects of licorice consumed as food: An update]. Rev Med Interne 2023; 44:487-494. [PMID: 37005098 DOI: 10.1016/j.revmed.2023.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 02/07/2023] [Accepted: 03/09/2023] [Indexed: 04/03/2023]
Abstract
The word "licorice" refers to the plant, its root, and its aromatic extract. From a commercial point of view, Glycyrrhiza glabra is the most important species with a wide range of uses (herbal medicine, tobacco industry, cosmetics, food and pharmaceutical). Glycyrrhizin is one of the main constituents of licorice. Glycyrrhizin is hydrolyzed in the intestinal lumen by bacterial β-glucuronidases to 3β-monoglucuronyl-18β-glycyrrhetinic acid (3MGA) and 18β-glycyrrhetinic acid (GA), which are metabolized in the liver. Plasma clearance is slow due to enterohepatic cycling. 3MGA and GA can bind to mineralocorticoid receptors with very low affinity, and 3MGA induces apparent mineralocorticoid excess syndrome through dose-dependent inhibition of 11β-hydroxysteroid dehydrogenase type 2 in renal tissue. The cases of apparent mineralocorticoid excess syndrome reported in the literature are numerous and sometimes severe, even fatal, most often in cases of chronic high dose consumption. Glycyrrhizin poisonings are characterized by hypertension, fluid retention, and hypokalemia with metabolic alkalosis and increased kaliuresis. Toxicity depends on the dose, the type of product consumed, the mode of consumption (acute or chronic) and a very large inter-individual variability. The diagnosis of glycyrrhizin-induced apparent mineralocorticoid excess syndrome is based on the history, clinical examination, and biochemical analysis. Management is primarily based on symptomatic care and stopping licorice consumption.
Collapse
Affiliation(s)
- W Caré
- Centre antipoison de Paris, Fédération de toxicologie (FeTox), hôpital Fernand-Widal (AP-HP), 200, rue du faubourg Saint-Denis, 75010 Paris, France; Service de médecine interne, hôpital d'instruction des armées Bégin, 69, avenue de Paris, 91460 Saint-Mandé, France; Université Paris Cité, Inserm UMR-S 1144, optimisation thérapeutique en neuropsychopharmacologie, 75006 Paris, France.
| | - G Grenet
- Service hospitalo-universitaire de pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France; UMR - CNRS 5558, laboratoire de biométrie et biologie évolutive, université Lyon 1, 69000 Lyon, France; Université de Lyon, Université Lyon 1, 69000 Lyon, France
| | - C Schmitt
- Pharmacologie clinique, centre antipoison et de toxicovigilance de Marseille, APHM, Hôpitaux Sud, Marseille, France
| | - S Michel
- Produit naturel, analyse et synthèse, UMR CNRS 8038, UFR Pharmacie, université Paris Cité, 4, avenue de l'Observatoire, 75006 Paris, France
| | - J Langrand
- Centre antipoison de Paris, Fédération de toxicologie (FeTox), hôpital Fernand-Widal (AP-HP), 200, rue du faubourg Saint-Denis, 75010 Paris, France; Université Paris Cité, Inserm UMR-S 1144, optimisation thérapeutique en neuropsychopharmacologie, 75006 Paris, France
| | - G Le Roux
- Centre antipoison d'Angers, Centre hospitalier universitaire d'Angers, 4, rue Larrey, 49000 Angers, France; Institut de recherche en santé, environnement et travail (IRSET), Inserm UMR 1085, équipe 10 ESTER, université d'Angers, 49000 Angers, France
| | - D Vodovar
- Centre antipoison de Paris, Fédération de toxicologie (FeTox), hôpital Fernand-Widal (AP-HP), 200, rue du faubourg Saint-Denis, 75010 Paris, France; Université Paris Cité, Inserm UMR-S 1144, optimisation thérapeutique en neuropsychopharmacologie, 75006 Paris, France; UFR de médecine, université de Paris, 75006 Paris, France
| |
Collapse
|
4
|
Kirschner J, Michel S, Becker R, Stiebitz O, Hommel H, Schulz R, Daszkiewicz M, Królikowska A, Prill R. Determination of Relationships between Symmetry-Based, Performance-Based, and Functional Outcome Measures in Patients Undergoing Total Hip Arthroplasty. J Pers Med 2023; 13:1046. [PMID: 37511659 PMCID: PMC10381123 DOI: 10.3390/jpm13071046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 06/06/2023] [Accepted: 06/23/2023] [Indexed: 07/30/2023] Open
Abstract
Due to the high heterogeneity in outcome measures after total hip arthroplasty (THA), the prospective observational study investigated the relationships between symmetry-based (SBMs), performance-based (PBMs), and functional outcome measures in THA patients to determine necessary or redundant categories of tests. The study material consisted of 24 patients with end-stage hip osteoarthritis scheduled for THA. The patients were examined one day before surgery and consecutively on the 4th day, 9th day, and 10th week postoperatively using the SBMs (weight-bearing chair-rising test, measurements of the maximal isometric torque of the quadriceps muscle); the PBMs (10-m walk, timed up-and-go, and stair-climbing tests); and the functional outcome measure (Harris Hip Score). The results obtained in a given category of tests at different time points were compared, and the correlations between the tests were determined. The reliability of the outcome measures was determined. The results of tests in the studied categories statistically significantly (p < 0.05) improved at the 10th week postoperatively compared to preoperative results. No strong correlations were revealed between the three studied types of outcome measures in THA patients. Therefore, none of them can be considered redundant. It also means that the relevance of symmetry for a core measurement set to describe the domain function in THA patients must be further clarified.
Collapse
Affiliation(s)
- Jana Kirschner
- Department of Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg, 03046 Cottbus, Germany
| | - Sven Michel
- Department of Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg, 03046 Cottbus, Germany
| | - Roland Becker
- Center of Orthopaedics and Traumatology, University Hospital Brandenburg a.d.H., Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
- Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
| | - Olaf Stiebitz
- Department of Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg, 03046 Cottbus, Germany
| | - Hagen Hommel
- Department of Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg, 03046 Cottbus, Germany
- District Hospital Märkisch Oderland GmbH, 16269 Wriezen, Germany
| | - Robert Schulz
- BIH QUEST Center for Responsible Research, Berlin Institute of Health at Charité, Universitätsmedizin Berlin, 10178 Berlin, Germany
| | | | - Aleksandra Królikowska
- Ergonomics and Biomedical Monitoring Laboratory, Department of Physiotherapy, Faculty of Health Sciences, Wroclaw Medical University, 50367 Wroclaw, Poland
| | - Robert Prill
- Center of Orthopaedics and Traumatology, University Hospital Brandenburg a.d.H., Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
- Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
| |
Collapse
|
5
|
Kaufmann B, de Los Reyes Jiménez M, Booshehri LM, Onyuru J, Leszczynska A, Uri A, Michel S, Klar R, Jaschinski F, Feldstein AE, Broderick L, Hoffman HM. Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice. J Immunol 2023:263844. [PMID: 37256266 DOI: 10.4049/jimmunol.2200550] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 05/08/2023] [Indexed: 06/01/2023]
Abstract
Antisense oligonucleotides (ASOs) are a novel therapeutic strategy that targets a specific gene and suppresses its expression. The cryopyrin-associated periodic syndromes (CAPS) are a spectrum of autoinflammatory diseases characterized by systemic and tissue inflammation that is caused by heterozygous gain-of-function mutations in the nucleotide-binding and oligomerization domain-like receptor (NLR) family pyrin domain containing 3 (NLRP3) gene. The aim of this study was to investigate the efficacy of an Nlrp3-specific ASO treatment in CAPS. An Nlrp3-specific ASO was designed and tested in murine cell lines and bone marrow-derived macrophages (BMDMs) from wild-type and CAPS mouse models. Nlrp3 knock-in mice were treated in vivo with Nlrp3-specific ASO, survival was monitored, and expression of organ-specific Nlrp3 and IL-1β was measured. Nlrp3-specific ASO treatment of murine cell lines and BMDMs showed a significant downregulation of Nlrp3 and mature IL-1β protein expression. Ex vivo treatment of Nlrp3 mutant mouse-derived BMDMs with Nlrp3-specific ASO demonstrated significantly reduced IL-1β release. In vivo, Nlrp3-specific ASO treatment of Nlrp3 mutant mice prolonged survival, reduced systemic inflammation, and decreased tissue-specific expression of Nlrp3 and mature IL-1β protein. The results of this study demonstrate that Nlrp3-specific ASO treatment downregulates Nlrp3 expression and IL-1β release in CAPS models, suggesting ASO therapy as a potential treatment of CAPS and other NLRP3-mediated diseases.
Collapse
Affiliation(s)
- Benedikt Kaufmann
- Department of Pediatrics, University of California San Diego, La Jolla, CA
- Klinik und Poliklinik für Chirurgie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | | | - Laela M Booshehri
- Department of Pediatrics, University of California San Diego, La Jolla, CA
| | - Janset Onyuru
- Department of Pediatrics, University of California San Diego, La Jolla, CA
| | | | - Anna Uri
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg/Martinsried, Germany
| | - Sven Michel
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg/Martinsried, Germany
| | - Richard Klar
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg/Martinsried, Germany
| | - Frank Jaschinski
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg/Martinsried, Germany
| | - Ariel E Feldstein
- Department of Pediatrics, University of California San Diego, La Jolla, CA
- Rady Children's Hospital-San Diego, San Diego, CA
| | - Lori Broderick
- Department of Pediatrics, University of California San Diego, La Jolla, CA
- Rady Children's Hospital-San Diego, San Diego, CA
| | - Hal M Hoffman
- Department of Pediatrics, University of California San Diego, La Jolla, CA
- Rady Children's Hospital-San Diego, San Diego, CA
| |
Collapse
|
6
|
Fernandez-Rodriguez L, Cianciaruso C, Bill R, Trefny MP, Klar R, Kirchhammer N, Buchi M, Festag J, Michel S, Kohler RH, Jones E, Maaske A, Vom Berg J, Kobold S, Kashyap AS, Jaschinski F, Dixon KO, Pittet MJ, Zippelius A. Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity. J Immunother Cancer 2023; 11:e006714. [PMID: 37208130 PMCID: PMC10201251 DOI: 10.1136/jitc-2023-006714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/16/2023] [Indexed: 05/21/2023] Open
Abstract
BACKGROUND Although immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing network linking innate and adaptive immunity. Here, we present an antisense oligonucleotide (ASO)-based strategy that dually targets toll-like receptor 9 (TLR9) and programmed cell death ligand 1 (PD-L1), aiming to overcome resistance to anti-PD-L1 monoclonal therapy. METHODS We designed a high-affinity immunomodulatory IM-TLR9:PD-L1-ASO antisense oligonucleotide (hereafter, IM-T9P1-ASO) targeting mouse PD-L1 messenger RNA and activating TLR9. Then, we performed in vitro and in vivo studies to validate the IM-T9P1-ASO activity, efficacy, and biological effects in tumors and draining lymph nodes. We also performed intravital imaging to study IM-T9P1-ASO pharmacokinetics in the tumor. RESULTS IM-T9P1-ASO therapy, unlike PD-L1 antibody therapy, results in durable antitumor responses in multiple mouse cancer models. Mechanistically, IM-T9P1-ASO activates a state of tumor-associated dendritic cells (DCs), referred to here as DC3s, which have potent antitumor potential but express the PD-L1 checkpoint. IM-T9P1-ASO has two roles: it triggers the expansion of DC3s by engaging with TLR9 and downregulates PD-L1, thereby unleashing the antitumor functions of DC3s. This dual action leads to tumor rejection by T cells. The antitumor efficacy of IM-T9P1-ASO depends on the antitumor cytokine interleukin-12 (IL-12), produced by DC3s, and Batf3, a transcription factor required for DC development. CONCLUSIONS By simultaneously targeting TLR9 and PD-L1, IM-T9P1-ASO amplifies antitumor responses via DC activation, leading to sustained therapeutic efficacy in mice. By highlighting differences and similarities between mouse and human DCs, this study could serve to develop similar therapeutic strategies for patients with cancer.
Collapse
Affiliation(s)
| | - Chiara Cianciaruso
- Department of Pathology and Immunology, University of Geneva, Geneve, Switzerland
- AGORA Cancer Research Center, Lausanne, Switzerland
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA
| | - Ruben Bill
- Department of Pathology and Immunology, University of Geneva, Geneve, Switzerland
- AGORA Cancer Research Center, Lausanne, Switzerland
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA
| | - Marcel P Trefny
- Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland
| | - Richard Klar
- Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany
| | - Nicole Kirchhammer
- Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland
| | - Mélanie Buchi
- Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland
| | - Julia Festag
- Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany
| | - Sven Michel
- Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany
| | - Rainer H Kohler
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA
| | - Elham Jones
- Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland
| | - Andre Maaske
- Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany
| | - Johannes Vom Berg
- Institute of Laboratory Animal Science, University of Zurich, Zürich, Switzerland
| | - Sebastian Kobold
- Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany
- German Center for Lung Research (DZL), German Center for Translational Cancer Research (DKTK), partner site Munich, Munich, Germany
| | - Abhishek S Kashyap
- Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland
| | - Frank Jaschinski
- Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany
| | - Karen O Dixon
- Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland
| | - Mikael J Pittet
- Department of Pathology and Immunology, University of Geneva, Geneve, Switzerland
- AGORA Cancer Research Center, Lausanne, Switzerland
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA
- Ludwig Institute for Cancer Research Lausanne Branch, Lausanne, Switzerland
| | - Alfred Zippelius
- Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland
- Department of Medical Oncology, University Hospital Basel, Basel, Switzerland
| |
Collapse
|
7
|
Glueck O, Kovacs J, Corradini S, Fertmann J, Sienel W, Kauke T, Hatz R, Michel S, Irlbeck M, Kneidinger N, Schneider C. Brachytherapy Treatment for Bronchial Anastomosis Narrowing After Invasive Aspergillosis. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
8
|
Garcia-Abadillo J, Morales L, Buerstmayr H, Michel S, Lillemo M, Holzapfel J, Hartl L, Akdemir D, Carvalho HF, Isidro-Sánchez J. Alternative scoring methods of fusarium head blight resistance for genomic assisted breeding. Front Plant Sci 2023; 13:1057914. [PMID: 36714712 PMCID: PMC9876611 DOI: 10.3389/fpls.2022.1057914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Accepted: 11/24/2022] [Indexed: 06/18/2023]
Abstract
Fusarium head blight (FHB) is a fungal disease of wheat (Triticum aestivum.L) that causes yield losses and produces mycotoxins which could easily exceed the limits of the EU regulations. Resistance to FHB has a complex genetic architecture and accurate evaluation in breeding programs is key to selecting resistant varieties. The Area Under the Disease Progress Curve (AUDPC) is one of the commonly metric used as a standard methodology to score FHB. Although efficient, AUDPC requires significant costs in phenotyping to cover the entire disease development pattern. Here, we show that there are more efficient alternatives to AUDPC (angle, growing degree days to reach 50% FHB severity, and FHB maximum variance) that reduce the number of field assessments required and allow for fair comparisons between unbalanced evaluations across trials. Furthermore, we found that the evaluation method that captures the maximum variance in FHB severity across plots is the most optimal approach for scoring FHB. In addition, results obtained on experimental data were validated on a simulated experiment where the disease progress curve was modeled as a sigmoid curve with known parameters and assessment protocols were fully controlled. Results show that alternative metrics tested in this study captured key components of quantitative plant resistance. Moreover, the new metrics could be a starting point for more accurate methods for measuring FHB in the field. For example, the optimal interval for FHB evaluation could be predicted using prior knowledge from historical weather data and FHB scores from previous trials. Finally, the evaluation methods presented in this study can reduce the FHB phenotyping burden in plant breeding with minimal losses on signal detection, resulting in a response variable available to use in data-driven analysis such as genome-wide association studies or genomic selection.
Collapse
Affiliation(s)
- J. Garcia-Abadillo
- Department of Biotechnology and Plant Biology - Centre for Biotechnology and Plant Genomics (CBGP) - Universidad Politécnica de Madrid (UPM), Madrid, Spain
| | - L. Morales
- Department of Agrobiotechnology, Institute of Biotechnology in Plant Production, University of Natural Resources and Life Sciences Vienna (BOKU), Tulln an der Donau, Austria
| | - H. Buerstmayr
- Department of Agrobiotechnology, Institute of Biotechnology in Plant Production, University of Natural Resources and Life Sciences Vienna (BOKU), Tulln an der Donau, Austria
| | - S. Michel
- Department of Agrobiotechnology, Institute of Biotechnology in Plant Production, University of Natural Resources and Life Sciences Vienna (BOKU), Tulln an der Donau, Austria
| | - M. Lillemo
- Department of Plant Sciences, Norwegian University of Life Sciences (NMBU), Ås, Norway
| | | | - L. Hartl
- Bavarian State Research Center for Agriculture, Institute for Crop Science and Plant Breeding, Freising, Germany
| | - D. Akdemir
- CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN, United States
| | - H. F. Carvalho
- Department of Biotechnology and Plant Biology - Centre for Biotechnology and Plant Genomics (CBGP) - Universidad Politécnica de Madrid (UPM), Madrid, Spain
| | - J. Isidro-Sánchez
- Department of Biotechnology and Plant Biology - Centre for Biotechnology and Plant Genomics (CBGP) - Universidad Politécnica de Madrid (UPM), Madrid, Spain
| |
Collapse
|
9
|
Cieśla E, Suliga E, Kadučáková H, Michel S, Ižová M, Simočková V, Martin T, Braun A, Kozieł D, Głuszek S. Reproducibility of the German and Slovakian Versions of the Dietary Habits and Nutrition Beliefs Questionnaire (KomPAN). Nutrients 2022; 14:nu14224893. [PMID: 36432579 PMCID: PMC9696161 DOI: 10.3390/nu14224893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 11/11/2022] [Accepted: 11/16/2022] [Indexed: 11/22/2022] Open
Abstract
PURPOSE The aim of this study was to assess the reproducibility and reliability of the KomPAN questionnaire among two groups of university students from Germany and Slovakia. METHODS A total of 422 individuals (mean age 21.4 years, SD 4.0), including 197 from Slovakia (men 26.2%) and 225 from Germany (men 22.3%), were tested using the self-administered (SA-Q) version of the KomPAN questionnaire and then retested two weeks later. A cross-classification analysis, kappa coefficients, Cronbach's ɑ coefficients, and a test-retest result comparison were conducted separately for each group of students to assess the reproducibility and reliability of the questionnaire. RESULTS The cross-classification values were higher than 46.2% among the German students and higher than 55.8% among the Slovakian students. The kappa coefficients ranged from 0.21 to 0.90 in the German students and from 0.38 to 0.94 in the Slovakian students. Cronbach's ɑ ranged from 0.58 to 0.78. CONCLUSION The questionnaire displayed a moderate to very good reproducibility, which was slightly higher in the Slovakian group than in the German group. Therefore, the questionnaire can be recommended for further analysis and comparison of the dietary habits among Germans and Slovakians on a larger scale.
Collapse
Affiliation(s)
- Elżbieta Cieśla
- Institute of Health Sciences, Medical College, Jan Kochanowski University, 25-369 Kielce, Poland
- Correspondence:
| | - Edyta Suliga
- Institute of Health Sciences, Medical College, Jan Kochanowski University, 25-369 Kielce, Poland
| | - Helena Kadučáková
- Department of Nursing, Faculty of Health, Catholic University in Ružomberok, 03401 Ružomberok, Slovakia
| | - Sven Michel
- Institute for Health, Faculty of Social Work, Health and Music, Brandenburg University of Technology Cottbus-Senftenberg, 03048 Cottbus, Germany
| | - Marcela Ižová
- Institute for Health, Faculty of Social Work, Health and Music, Brandenburg University of Technology Cottbus-Senftenberg, 03048 Cottbus, Germany
| | - Viera Simočková
- Department of Nursing, Faculty of Health, Catholic University in Ružomberok, 03401 Ružomberok, Slovakia
| | - Titus Martin
- Institute for Health, Faculty of Social Work, Health and Music, Brandenburg University of Technology Cottbus-Senftenberg, 03048 Cottbus, Germany
| | - Alexander Braun
- Institute for Health, Faculty of Social Work, Health and Music, Brandenburg University of Technology Cottbus-Senftenberg, 03048 Cottbus, Germany
| | - Dorota Kozieł
- Institute of Medical Sciences, Medical College, Jan Kochanowski University, 25-369 Kielce, Poland
| | - Stanisław Głuszek
- Institute of Medical Sciences, Medical College, Jan Kochanowski University, 25-369 Kielce, Poland
| |
Collapse
|
10
|
Prill R, Becker R, Schulz R, Michel S, Hommel H. No correlation between symmetry-based performance measures and patient-related outcome prior to and after total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc 2022; 30:3155-3161. [PMID: 33881572 DOI: 10.1007/s00167-021-06570-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Accepted: 04/06/2021] [Indexed: 12/01/2022]
Abstract
PURPOSE Standardized outcome measures are crucial for the evaluation of different treatment and rehabilitation regimes in patients after total knee arthroplasty (TKA). Performance-based measures are necessary to capture different aspects of physical function. High reliability and agreement of five performance-based measures were hypothesized to differentiate between measurement error and change in test performance. Secondary outcomes are the correlation of performance-based measurements to KSS and WOMAC prior to surgery (baseline) and 10 weeks thereafter (t3). METHODS The test-retest reliabilities and agreements of the 1-m walk test, the stair-climbing test, the timed-up-and-go test, the weight-balanced-chair-rising test and the isometric maximum knee extension force in patients undergoing total knee replacements were studied. The intraclass correlation coefficient was calculated and a Bland-Altman analysis performed. RESULTS The weight-balanced-chair-rising test showed a symmetry at baseline = 0.77, 5 ± 1 days after surgery (t1) = 0.50, 9 ± 1 days (t2) = 0.59 and (t3) = 0.80. All performance tests showed high intraclass correlation coefficients (ICC = 0.81-0.99). The 10-m walk test, stair climbing test, and the timed-up-and-go test showed high agreement in the Bland-Altman analysis. The Bland-Altman analysis for the weight-balanced-chair-rising test and isometric knee extension force indicated high agreement at 5 and 9 days postoperatively, but the relative measurement error increased pre- and 10 weeks postoperatively. CONCLUSION In conclusion, symmetry, as an important outcome after TKA, is a reliable and rather unique item that should unquestionably be added to established measurements like walking tests or survey-based function assessment. The implementation of standardized performance-based measures to assess physical function in rehabilitation procedures will help to improve the more objectively based assessment of different rehabilitation protocols. LEVEL OF EVIDENCE II.
Collapse
Affiliation(s)
- Robert Prill
- Department of Orthopedics and Traumatology, Centre of Joint Replacement West Brandenburg, Brandenburg Medical School Theodor Fontane, Hochstraße 29, 14770, Brandenburg, Germany.
| | - Roland Becker
- Department of Orthopedics and Traumatology, Centre of Joint Replacement West Brandenburg, Brandenburg Medical School Theodor Fontane, Hochstraße 29, 14770, Brandenburg, Germany
| | - Robert Schulz
- Berlin Institute of Health Quest Center, Berlin, Germany
| | - Sven Michel
- Brandenburg University of Technology-CS, Senftenberg, Germany
| | - Hagen Hommel
- Department of Orthopedics and Traumatology, Centre of Joint Replacement West Brandenburg, Brandenburg Medical School Theodor Fontane, Hochstraße 29, 14770, Brandenburg, Germany
- District Hospital Märkisch Oderland GmbH, Wriezen, Germany
| |
Collapse
|
11
|
Deng M, Kutrolli E, Sadewasser A, Michel S, Joibari MM, Jaschinski F, Olivecrona G, Nilsson SK, Kersten S. ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy. J Lipid Res 2022; 63:100237. [PMID: 35667416 PMCID: PMC9270256 DOI: 10.1016/j.jlr.2022.100237] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Revised: 04/30/2022] [Accepted: 05/31/2022] [Indexed: 11/17/2022] Open
Abstract
Angiopoietin-like 4 (ANGPTL4) is an important regulator of plasma triglyceride (TG) levels and an attractive pharmacological target for lowering plasma lipids and reducing cardiovascular risk. Here, we aimed to study the efficacy and safety of silencing ANGPTL4 in the livers of mice using hepatocyte-targeting GalNAc-conjugated antisense oligonucleotides (ASOs). Compared with injections with negative control ASO, four injections of two different doses of ANGPTL4 ASO over 2 weeks markedly downregulated ANGPTL4 levels in liver and adipose tissue, which was associated with significantly higher adipose LPL activity and lower plasma TGs in fed and fasted mice, as well as lower plasma glucose levels in fed mice. In separate experiments, injection of two different doses of ANGPTL4 ASO over 20 weeks of high-fat feeding reduced hepatic and adipose ANGPTL4 levels but did not trigger mesenteric lymphadenopathy, an acute phase response, chylous ascites, or any other pathological phenotypes. Compared with mice injected with negative control ASO, mice injected with ANGPTL4 ASO showed reduced food intake, reduced weight gain, and improved glucose tolerance. In addition, they exhibited lower plasma TGs, total cholesterol, LDL-C, glucose, serum amyloid A, and liver TG levels. By contrast, no significant difference in plasma alanine aminotransferase activity was observed. Overall, these data suggest that ASOs targeting ANGPTL4 effectively reduce plasma TG levels in mice without raising major safety concerns.
Collapse
Affiliation(s)
- Mingjuan Deng
- Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, the Netherlands
| | - Elda Kutrolli
- Lipigon Pharmaceuticals AB, Tvistevägen 48C, 907 36, Umeå, Sweden
| | - Anne Sadewasser
- Secarna Pharmaceuticals GmbH & Co. KG, Am Klopferspitz 19, 82152 Planegg, Germany
| | - Sven Michel
- Secarna Pharmaceuticals GmbH & Co. KG, Am Klopferspitz 19, 82152 Planegg, Germany
| | | | - Frank Jaschinski
- Secarna Pharmaceuticals GmbH & Co. KG, Am Klopferspitz 19, 82152 Planegg, Germany
| | - Gunilla Olivecrona
- Lipigon Pharmaceuticals AB, Tvistevägen 48C, 907 36, Umeå, Sweden; Department of Medical Biosciences, Umeå University, SE-901 87, Umeå, Sweden
| | - Stefan K Nilsson
- Lipigon Pharmaceuticals AB, Tvistevägen 48C, 907 36, Umeå, Sweden
| | - Sander Kersten
- Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, the Netherlands.
| |
Collapse
|
12
|
Paalvast I, Michel S, Geel A, Adriaens N, Keijzers N, Gulmans V, Zwitserloot A, Bannier M, van der RM, Zomer D. P051 Improved opportunities for trial participation via the Dutch CF Trial Consortium. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00384-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
13
|
Hermann M, Pabst-Von OJ, Michel S, Dalla-Pozza R, Jakob A, Hörer J, Haas N. First in Man: Successful Implantation of a Custom-Made Fontan Cannula in a Patient with Failing Fontan Circulation as a Bridge to Transplant. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | | | | | | | - A. Jakob
- Lindwurmstr. 4, München, Deutschland
| | | | | |
Collapse
|
14
|
Rosenthal LL, Hagl C, Pichlmaier M, Michel S, Zimmerling L, Haas N, Ulrich SM, Hörer J. Long-Term Outcome following Pediatric Heart Transplantation with and without Mechanical Circulatory Support as Bridge to Transplantation: Eight Patient-Years on Assist and 1,480 Patient-Years following Transplantation. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- L. L. Rosenthal
- Department for Cardiac Surgery - Pediatric Heart Surgery, LMU Klinikum München, München, Deutschland
| | - C. Hagl
- Department for Cardiac Surgery, LMU Klinikum München, Munich, Deutschland
| | - M. Pichlmaier
- Department for Cardiac Surgery, LMU Klinikum München, Munich, Deutschland
| | - S. Michel
- Department for Cardiac Surgery - Pediatric Heart Surgery, LMU Klinikum München, Munich, Deutschland
| | - L. Zimmerling
- Department for Cardiac Surgery, LMU Klinikum München, Munich, Deutschland
| | - N. Haas
- Department for Pediatric Cardiology, LMU Klinikum München, Munich, Deutschland
| | - S. M. Ulrich
- Department for Pediatric Cardiology, LMU Klinikum München, Munich, Deutschland
| | - J. Hörer
- Department for Cardiac Surgery, LMU Klinikum München, Pediatric Heart Surgery, Munich, Deutschland
| |
Collapse
|
15
|
Schulte-Döinghaus S, Liu H, Michel S, Hagl C, Yildirim AO, Dashkevich A. The Role of VEGF-C Precursors in the Macrophage-Mediated Activation of VEGFR3 Signaling in Lymphatic Endothelium In Vitro. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- S. Schulte-Döinghaus
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, München, Deutschland
| | - H. Liu
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, München, Deutschland
| | - S. Michel
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, München, Deutschland
| | - C. Hagl
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, München, Deutschland
| | - A. O. Yildirim
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Oberschleißheim, Deutschland
| | - A. Dashkevich
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, München, Deutschland
| |
Collapse
|
16
|
Liu H, Hollauer C, Hagle C, Michel S, Yildirim AO, Dashkevich A. Extended Cold Ischemia and Indirect Alloimmunity Are Fundamental for the Development of Chronic Lung Allograft Dysfunction. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- H. Liu
- Department of Cardiac Surgery, Ludwig Maximilian University of Munich, München, Deutschland
| | - C. Hollauer
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), München, Deutschland
| | - C. Hagle
- Department of Cardiac Surgery, Ludwig Maximilian University of Munich, München, Deutschland
| | - S. Michel
- Department of Cardiac Surgery, Ludwig Maximilian University of Munich, München, Deutschland
| | - A. O. Yildirim
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), München, Deutschland
| | - A. Dashkevich
- Department of Cardiac Surgery, Ludwig Maximilian University of Munich, München, Deutschland
| |
Collapse
|
17
|
Shahzad K, Fatima S, Al-Dabet MM, Gadi I, Khawaja H, Ambreen S, Elwakiel A, Klöting N, Blüher M, Nawroth PP, Mertens PR, Michel S, Jaschinski F, Klar R, Isermann B. CHOP-ASO Ameliorates Glomerular and Tubular Damage on Top of ACE Inhibition in Diabetic Kidney Disease. J Am Soc Nephrol 2021; 32:3066-3079. [PMID: 34479965 PMCID: PMC8638397 DOI: 10.1681/asn.2021040431] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Accepted: 08/21/2021] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Maladaptive endoplasmic reticulum stress signaling in diabetic kidney disease (DKD) is linked to increased glomerular and tubular expression of the cell-death-promoting transcription factor C/EBP homologous protein (CHOP). Here, we determined whether locked nucleic acid (LNA)-modified antisense oligonucleotides (ASOs) targeting CHOP ameliorate experimental DKD. METHODS We determined the efficacy of CHOP-ASO in the early and late stages of experimental DKD (in 8- or 16-week-old db/db mice, respectively) alone or with an angiotensin-converting enzyme inhibitor (ACEi), after an in vivo dose-escalation study. We used renal functional parameters and morphologic analyses to assess the effect of CHOP-ASO and renal gene-expression profiling to identify differentially regulated genes and pathways. Several human CHOP-ASOs were tested in hyperglycemia-exposed human kidney cells. RESULTS CHOP-ASOs efficiently reduced renal CHOP expression in diabetic mice and reduced markers of DKD at the early and late stages. Early combined intervention (CHOP-ASO and ACEi) efficiently prevented interstitial damage. At the later timepoint, the combined treatment reduced indices of both glomerular and tubular damage more efficiently than either intervention alone. CHOP-ASO affected a significantly larger number of genes and disease pathways, including reduced sodium-glucose transport protein 2 (Slc5a2) and PROM1 (CD133). Human CHOP-ASOs efficiently reduced glucose-induced CHOP and prevented death of human kidney cells in vitro . CONCLUSIONS The ASO-based approach efficiently reduced renal CHOP expression in a diabetic mouse model, providing an additional benefit to an ACEi, particularly at later timepoints. These studies demonstrate that ASO-based therapies efficiently reduce maladaptive CHOP expression and ameliorate experimental DKD.
Collapse
Affiliation(s)
- Khurrum Shahzad
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Department of Diagnostics, University Hospital Leipzig, Leipzig, Germany
| | - Sameen Fatima
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Department of Diagnostics, University Hospital Leipzig, Leipzig, Germany,Institute of Experimental Internal Medicine, Department of Internal Medicine, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - Moh’d Mohanad Al-Dabet
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Department of Diagnostics, University Hospital Leipzig, Leipzig, Germany,Department of Medical Laboratories, American University of Madaba, Amman, Jordan
| | - Ihsan Gadi
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Department of Diagnostics, University Hospital Leipzig, Leipzig, Germany
| | - Hamzah Khawaja
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Department of Diagnostics, University Hospital Leipzig, Leipzig, Germany
| | - Saira Ambreen
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Department of Diagnostics, University Hospital Leipzig, Leipzig, Germany
| | - Ahmed Elwakiel
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Department of Diagnostics, University Hospital Leipzig, Leipzig, Germany
| | - Nora Klöting
- Helmholtz Institute for Metabolic, Obesity and Vascular Research of the Helmholtz Zentrum München at the University of Leipzig, Leipzig, Germany
| | - Matthias Blüher
- Helmholtz Institute for Metabolic, Obesity and Vascular Research of the Helmholtz Zentrum München at the University of Leipzig, Leipzig, Germany,Medical Department III, Endocrinology, Nephrology, Rheumatology, University Hospital Leipzig, Leipzig, Germany
| | - Peter P. Nawroth
- Internal Medicine I and Clinical Chemistry, German Diabetes Center, Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany
| | - Peter R. Mertens
- Clinic of Nephrology and Hypertension, Diabetes and Endocrinology, Department of Internal Medicine, Otto-von-Guericke University, Magdeburg, Germany
| | - Sven Michel
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
| | | | - Richard Klar
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
| | - Berend Isermann
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Department of Diagnostics, University Hospital Leipzig, Leipzig, Germany
| |
Collapse
|
18
|
Muilwijk D, de Poel E, van Mourik P, Suen S, Vonk A, Brunsveld J, Kruisselbrink E, Oppelaar H, Hagemeijer M, Berkers G, de Winter-de Groot K, Michel S, Jans S, van Panhuis H, van der Eerden M, van der Meer R, Roukema J, Dompeling E, Weersink E, Koppelman G, Vries R, Zomer-van Ommen D, Eijkemans R, van der Ent C, Beekman J. 665: Forskolin-induced intestinal organoid swelling predicts long-term cystic fibrosis disease progression. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02088-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Michel S, Klar R, Jaschinski F. Investigation of the Activity of Antisense Oligonucleotides Targeting Multiple Genes by RNA-Sequencing. Nucleic Acid Ther 2021; 31:427-435. [PMID: 34251864 DOI: 10.1089/nat.2020.0932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Locked nucleic acid-modified antisense oligonucleotides (ASOs) can achieve strongly different degrees of target knockdown despite having similar biophysical properties and 100% homology with their target. The determinants for this observation remain largely unknown. We used multi-specific ASOs that have 100% sequence complementarity with a common target (IDO1) and a different number of diverse targets and investigated their effect on gene expression in a cell line by RNA-sequencing. We observed a significant higher chance for downregulation of long genes compared to short genes, of genes with high compared to lower expression, and of genes that have more than one binding site for the respective ASO. By investigating the expression of genes that have binding sites for more than one ASO we identified the individual binding site being an important determinant for activity. Under the selected experimental conditions we have not seen indications that availability of RNase H is a limiting factor as the number of degraded target RNA molecules correlated significantly with the number of predicted target RNA molecules. Taken together, by using multi-specific ASOs as tool compounds we identified determinants for ASO activity that can be taken into consideration to improve the selection process of highly potent and selective ASOs in the future.
Collapse
Affiliation(s)
- Sven Michel
- ISecarna Pharmaceuticals, GmbH & Co. KG, Planegg, Germany
| | - Richard Klar
- ISecarna Pharmaceuticals, GmbH & Co. KG, Planegg, Germany
| | | |
Collapse
|
20
|
Panagiotou M, Michel S, Meijer JH, Deboer T. The aging brain: sleep, the circadian clock and exercise. Biochem Pharmacol 2021; 191:114563. [PMID: 33857490 DOI: 10.1016/j.bcp.2021.114563] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2021] [Revised: 04/06/2021] [Accepted: 04/07/2021] [Indexed: 12/26/2022]
Abstract
Aging is a multifactorial process likely stemming from damage accumulation and/or a decline in maintenance and repair mechanisms in the organisms that eventually determine their lifespan. In our review, we focus on the morphological and functional alterations that the aging brain undergoes affecting sleep and the circadian clock in both human and rodent models. Although both species share mammalian features, differences have been identified on several experimental levels, which we outline in this review. Additionally, we delineate some challenges on the preferred analysis and we suggest that a uniform route is followed so that findings can be smoothly compared. We conclude by discussing potential interventions and highlight the influence of physical exercise as a beneficial lifestyle intervention, and its effect on healthy aging and longevity. We emphasize that even moderate age-matched exercise is able to ameliorate several aging characteristics as far as sleep and circadian rhythms are concerned, independent of the species studied.
Collapse
Affiliation(s)
- M Panagiotou
- Laboratory for Neurophysiology, Department of Cell and Chemical Biology, Leiden University Medical Center, The Netherlands.
| | - S Michel
- Laboratory for Neurophysiology, Department of Cell and Chemical Biology, Leiden University Medical Center, The Netherlands
| | - J H Meijer
- Laboratory for Neurophysiology, Department of Cell and Chemical Biology, Leiden University Medical Center, The Netherlands
| | - T Deboer
- Laboratory for Neurophysiology, Department of Cell and Chemical Biology, Leiden University Medical Center, The Netherlands
| |
Collapse
|
21
|
Shen M, Xie S, Rowicki M, Michel S, Wei Y, Hang X, Wan L, Lu X, Yuan M, Jin JF, Jaschinski F, Zhou T, Klar R, Kang Y. Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis. Cancer Res 2021; 81:1014-1025. [PMID: 33239430 PMCID: PMC8026491 DOI: 10.1158/0008-5472.can-20-1876] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 10/14/2020] [Accepted: 11/19/2020] [Indexed: 11/16/2022]
Abstract
Colorectal and lung cancers account for one-third of all cancer-related deaths worldwide. Previous studies suggested that metadherin (MTDH) is involved in the development of colorectal and lung cancers. However, how MTDH regulates the pathogenesis of these cancers remains largely unknown. Using genetically modified mouse models of spontaneous colorectal and lung cancers, we found that MTDH promotes cancer progression by facilitating Wnt activation and by inducing cytotoxic T-cell exhaustion, respectively. Moreover, we developed locked nucleic acid-modified (LNA) MTDH antisense oligonucleotides (ASO) that effectively and specifically suppress MTDH expression in vitro and in vivo. Treatments with MTDH ASOs in mouse models significantly attenuated progression and metastasis of colorectal, lung, and breast cancers. Our study opens a new avenue for developing therapies against colorectal and lung cancers by targeting MTDH using LNA-modified ASO. SIGNIFICANCE: This study provides new insights into the mechanism of MTDH in promoting colorectal and lung cancers, as well as genetic and pharmacologic evidence supporting the development of MTDH-targeting therapeutics.
Collapse
Affiliation(s)
- Minhong Shen
- Department of Molecular Biology, Princeton University, Princeton, New Jersey
| | - Shanshan Xie
- Department of Molecular Biology, Princeton University, Princeton, New Jersey
- Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou, China
- The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Cancer Center, Zhejiang University, Zhejiang, China
| | - Michelle Rowicki
- Department of Molecular Biology, Princeton University, Princeton, New Jersey
| | - Sven Michel
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg/Martinsried, Germany
| | - Yong Wei
- Department of Molecular Biology, Princeton University, Princeton, New Jersey
| | - Xiang Hang
- Department of Molecular Biology, Princeton University, Princeton, New Jersey
| | - Liling Wan
- Department of Molecular Biology, Princeton University, Princeton, New Jersey
| | - Xin Lu
- Department of Molecular Biology, Princeton University, Princeton, New Jersey
| | - Min Yuan
- Department of Molecular Biology, Princeton University, Princeton, New Jersey
| | - John F Jin
- Firebrand Therapeutics, Princeton, New Jersey
| | - Frank Jaschinski
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg/Martinsried, Germany
| | - Tianhua Zhou
- Cancer Center, Zhejiang University, Zhejiang, China
- Department of Cell Biology and Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Richard Klar
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg/Martinsried, Germany
| | - Yibin Kang
- Department of Molecular Biology, Princeton University, Princeton, New Jersey.
- Cancer Metabolism and Growth Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
| |
Collapse
|
22
|
Liu H, Zistler K, Aicha J, Hagl C, Yildirim AÖ, Michel S, Dashkevich A. Rapid Activation of Lymphangiogenesis Causes Increased Lymphatic Density during the Development of Chronic Lung Allograft Dysfunction. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
23
|
Englert L, Stadlbauer C, Spaeth M, Hofmann HS, Schneider C, Hatz RA, Preissler G, Michel S, Golovchenko S, Ried M, Hoenicka M. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model. Pulm Pharmacol Ther 2020; 66:101985. [PMID: 33359621 DOI: 10.1016/j.pupt.2020.101985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 11/13/2020] [Accepted: 12/09/2020] [Indexed: 10/22/2022]
Abstract
PURPOSE Medical combination therapy of pulmonary arterial hypertension (PAH) may alleviate the drawbacks of monotherapy by avoiding drug tolerance and by increasing effectiveness, as shown by the combination of ambrisentan and tadalafil (AMBITION trial). The present ex-vivo study evaluated the combination of the endothelin receptor antagonists (ERA) macitentan and bosentan with the phosphodiesterase-5 (PDE-5) inhibitor vardenafil in pulmonary arteries from patients suffering from terminal lung disease as a model of PAH. METHODS Segments of the pulmonary vessels were excised from resected lungs of patients requiring lung transplantation (LTX). Contraction of pulmonary arteries (PA) was elicited by consecutive dose-response curves of endothelin-1 (ET-1) followed by norepinephrine (NE) to allow inhibition by different pathways. Forces were measured isometrically in an organ bath in the presence and absence of ERA and PDE-5 inhibitors and their combination. RESULTS PA of 38 patients were examined between October 2016 and November 2019. Bosentan (1E-7 M) and macitentan (1E-8 M, 3E-8 M, 1E-7 M) inhibited ET-1 induced contractions, whereas vardenafil (1E-6 M, 3E-6 M, 1E-5 M) inhibited only the NE induced part of the contractions. Vardenafil enhanced bosentan-induced inhibition of vasoconstriction in a dose-dependent fashion. Combination effects exceeded single bosentan at 3E-6 M and 1E-5 M vardenafil, and they exceeded single vardenafil at the lower vardenafil concentrations. Macitentan showed a more pronounced inhibition than bosentan regardless of the lower concentrations. Accordingly, combination effects with vardenafil resembled those of macitentan alone. CONCLUSIONS Macitentan and bosentan were potent antagonists of vasoconstriction in PA of LTX patients. The benefit of drug combinations was demonstrated at selected concentrations only owing to a narrow therapeutic range of vardenafil in this ex-vivo model. These results suggest the utility of drug combinations other than the established pair of ambrisentan and tadalafil in PAH treatment but also make a case for a further assessment of vasodilator properties of drugs complementing ERA.
Collapse
Affiliation(s)
- L Englert
- Department of Thoracic Surgery, University Medical Center Regensburg, Germany.
| | - C Stadlbauer
- Department of Thoracic Surgery, University Medical Center Regensburg, Germany
| | - M Spaeth
- Department of Thoracic Surgery, University Medical Center Regensburg, Germany
| | - H S Hofmann
- Department of Thoracic Surgery, University Medical Center Regensburg, Germany
| | - C Schneider
- Department of Thoracic Surgery, Campus Großhadern, University of Munich, Germany
| | - R A Hatz
- Department of Thoracic Surgery, Campus Großhadern, University of Munich, Germany
| | - G Preissler
- Department of Thoracic Surgery, Hospital Schillerhöhe, Robert-Bosch-Hospital, Gerlingen, Germany
| | - S Michel
- Department of Cardiac Surgery, Campus Großhadern, University of Munich, Germany
| | - S Golovchenko
- Department of Thoracic Surgery, University Medical Center Regensburg, Germany
| | - M Ried
- Department of Thoracic Surgery, University Medical Center Regensburg, Germany
| | - M Hoenicka
- Department of Cardiothoracic and Vascular Surgery, University of Ulm Medical Center, Ulm, Germany
| |
Collapse
|
24
|
Michel S, Schirduan K, Shen Y, Klar R, Tost J, Jaschinski F. Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines. Mol Diagn Ther 2020; 25:77-85. [DOI: 10.1007/s40291-020-00504-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/20/2020] [Indexed: 12/12/2022]
|
25
|
Suliga E, Cieśla E, Michel S, Kaducakova H, Martin T, Śliwiński G, Braun A, Izova M, Lehotska M, Kozieł D, Głuszek S. Diet Quality Compared to the Nutritional Knowledge of Polish, German, and Slovakian University Students-Preliminary Research. Int J Environ Res Public Health 2020; 17:ijerph17239062. [PMID: 33291705 PMCID: PMC7730789 DOI: 10.3390/ijerph17239062] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 11/19/2020] [Accepted: 12/02/2020] [Indexed: 12/16/2022]
Abstract
The eating habits of students differ significantly from those recommended by health practitioners. The aim of this study was to find differences related to diet quality and knowledge on nutrition among Polish, German, and Slovakian students as well as to examine which factors differentiate the diet quality of students from these three countries. The study was conducted on a group of 394 university students from Poland, Germany, and Slovakia. The assessment of diet quality and knowledge on food and nutrition was done with the use of the Dietary Habits and Nutrition Beliefs Questionnaire. The diet of German students was characterized by a significantly higher consumption of legume-based foods, vegetables, and fruit compared to Polish students and Slovakian participants (p < 0.001). The diet of the Poles was characterized by a high consumption of cured meat, smoked sausages, hot dogs, white bread and bakery products, butter, fried foods, and energy drinks. The most important factors significantly associated with diet quality involved the country, place of residence, Body Mass Index (BMI), physical activity, and time spent watching TV or using a computer. Polish students were characterized by the highest level of knowledge on food and nutrition (p < 0.001). However, it was not reflected in their diet. The authorities of universities should aim to provide students with access to canteens on campuses which would offer the possibility of consumption of both affordable and healthy meals.
Collapse
Affiliation(s)
- Edyta Suliga
- Institute of Health Sciences, Medical College, Jan Kochanowski University, 25-369 Kielce, Poland; (E.S.); (D.K.)
| | - Elżbieta Cieśla
- Institute of Health Sciences, Medical College, Jan Kochanowski University, 25-369 Kielce, Poland; (E.S.); (D.K.)
- Correspondence:
| | - Sven Michel
- Institute of Ergonomics and Social Sciences, Faculty of Social Work, Health and Music, Brandenburg University of Technology Cottbus-Senftenberg, 03048 Cottbus, Germany; (S.M.); (T.M.); (A.B.)
| | - Helena Kaducakova
- Department of Nursing, Faculty of Health, Catholic University in Ružomberok, 03401 Ružomberok, Slovakia; (H.K.); (M.I.); (M.L.)
| | - Titus Martin
- Institute of Ergonomics and Social Sciences, Faculty of Social Work, Health and Music, Brandenburg University of Technology Cottbus-Senftenberg, 03048 Cottbus, Germany; (S.M.); (T.M.); (A.B.)
| | - Grzegorz Śliwiński
- Institute of Biomedical Engineering, Technical University in Dresden, 01069 Dresden, Germany;
| | - Alexander Braun
- Institute of Ergonomics and Social Sciences, Faculty of Social Work, Health and Music, Brandenburg University of Technology Cottbus-Senftenberg, 03048 Cottbus, Germany; (S.M.); (T.M.); (A.B.)
| | - Marcela Izova
- Department of Nursing, Faculty of Health, Catholic University in Ružomberok, 03401 Ružomberok, Slovakia; (H.K.); (M.I.); (M.L.)
| | - Maria Lehotska
- Department of Nursing, Faculty of Health, Catholic University in Ružomberok, 03401 Ružomberok, Slovakia; (H.K.); (M.I.); (M.L.)
| | - Dorota Kozieł
- Institute of Health Sciences, Medical College, Jan Kochanowski University, 25-369 Kielce, Poland; (E.S.); (D.K.)
| | - Stanisław Głuszek
- Institute of Medical Sciences, Medical College, Jan Kochanowski University, 25-369 Kielce, Poland;
| |
Collapse
|
26
|
Wienbergen H, Fach A, Meyer S, Schmucker J, Osteresch R, Michel S, Retzlaff T, Steckenborn M, Elsaesser A, Langer H, Hambrecht R. Long-term effects of an intensive prevention program (IPP) after acute myocardial infarction – the IPP Follow-up and Prevention Boost Trial. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The effects of an intensive prevention program (IPP) for 12 months following 3-week rehabilitation after myocardial infarction (MI) have been proven by the randomized IPP trial. The present study investigates if the effects of IPP persist one year after termination of the program and if a reintervention after >24 months (“prevention boost”) is effective.
Methods
In the IPP trial patients were recruited during hospitalization for acute MI and randomly assigned to IPP versus usual care (UC) one month after discharge (after 3-week rehabilitation). IPP was coordinated by non-physician prevention assistants and included intensive group education sessions, telephone calls, telemetric and clinical control of risk factors. Primary study endpoint was the IPP Prevention Score, a sum score evaluating six major risk factors. The score ranges from 0 to 15 points, with a score of 15 points indicating best risk factor control.
In the present study the effects of IPP were investigated after 24 months – one year after termination of the program. Thereafter, patients of the IPP study arm with at least one insufficiently controlled risk factor were randomly assigned to a 2-months reintervention (“prevention boost”) vs. no reintervention.
Results
At long-term follow-up after 24 months, 129 patients of the IPP study arm were compared to 136 patients of the UC study arm. IPP was associated with a significantly better risk factor control compared to UC at 24 months (IPP Prevention Score 10.9±2.3 points in the IPP group vs. 9.4±2.3 points in the UC group, p<0.01). However, in the IPP group a decrease of risk factor control was observed at the 24-months visit compared to the 12-months visit at the end of the prevention program (IPP Prevention Score 10.9±2.3 points at 24 months vs. 11.6±2.2 points at 12 months, p<0.05, Figure 1).
A 2-months reintervention (“prevention boost”) was effective to improve risk factor control during long-term course: IPP Prevention Score increased from 10.5±2.1 points to 10.7±1.9 points in the reintervention group, while it decreased from 10.5±2.1 points to 9.7±2.1 points in the group without reintervention (p<0.05 between the groups, Figure 1).
Conclusions
IPP was associated with a better risk factor control compared to UC during 24 months; however, a deterioration of risk factors after termination of IPP suggests that even a 12-months prevention program is not long enough. The effects of a short reintervention after >24 months (“prevention boost”) indicate the need for prevention concepts that are based on repetitive personal contacts during long-term course after coronary events.
Figure 1
Funding Acknowledgement
Type of funding source: Foundation. Main funding source(s): Stiftung Bremer Herzen (Bremen Heart Foundation)
Collapse
Affiliation(s)
- H Wienbergen
- Hospital Links der Weser, Bremen Institute for Heart and Circulation Research, Bremen, Germany
| | - A Fach
- Hospital Links der Weser, Bremen Institute for Heart and Circulation Research, Bremen, Germany
| | - S Meyer
- Heart Center Oldenburg, Oldenburg, Germany
| | - J Schmucker
- Hospital Links der Weser, Bremen Institute for Heart and Circulation Research, Bremen, Germany
| | - R Osteresch
- Hospital Links der Weser, Bremen Institute for Heart and Circulation Research, Bremen, Germany
| | - S Michel
- Hospital Links der Weser, Bremen Institute for Heart and Circulation Research, Bremen, Germany
| | - T Retzlaff
- Hospital Links der Weser, Bremen Institute for Heart and Circulation Research, Bremen, Germany
| | - M Steckenborn
- Hospital Links der Weser, Bremen Institute for Heart and Circulation Research, Bremen, Germany
| | | | - H Langer
- University Heart Center, Luebeck, Germany
| | - R Hambrecht
- Hospital Links der Weser, Bremen Institute for Heart and Circulation Research, Bremen, Germany
| |
Collapse
|
27
|
Abstract
Slow earthquakes, like regular earthquakes, result from unstable frictional slip. They produce little slip and can therefore repeat frequently. We assess their predictability using the slip history of the Cascadia subduction between 2007 and 2017, during which slow earthquakes have repeatedly ruptured multiple segments. We characterize the system dynamics using embedding theory and extreme value theory. The analysis reveals a low-dimensional (<5) nonlinear chaotic system rather than a stochastic system. We calculate properties of the underlying attractor like its correlation and instantaneous dimension, instantaneous persistence, and metric entropy. We infer that the system has a predictability horizon of the order of days weeks. For the better resolved segments, the onset of large slip events can be correctly forecasted by high values of the instantaneous dimension. Longer-term deterministic prediction seems intrinsically impossible. Regular earthquakes might similarly be predictable but with a limited predictable horizon of the order of their durations.
Collapse
Affiliation(s)
- A Gualandi
- California Institute of Technology, Pasadena, CA, USA.
| | - J-P Avouac
- California Institute of Technology, Pasadena, CA, USA
| | - S Michel
- Laboratoire de Géologie, Département de Géosciences, École Normale Supérieure, PSL University, UMR CNRS 8538, Paris, France
| | - D Faranda
- LSCE-IPSL, CEA Saclay l'Orme des Merisiers, CNRS UMR 8212 CEA-CNRS-UVSQ, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- London Mathematical Laboratory, London, UK
| |
Collapse
|
28
|
Prill R, Singh JA, Seeber GH, Nielsen SM, Goodman S, Michel S, Kopkow C, Schulz R, Choong P, Hommel H. Patient, physiotherapist and surgeon endorsement of the core domain set for total hip and total knee replacement in Germany: a study protocol for an OMERACT initiative. BMJ Open 2020; 10:e035207. [PMID: 32595152 PMCID: PMC7322286 DOI: 10.1136/bmjopen-2019-035207] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
INTRODUCTION There is a lack of harmonising measures for clinical trials on total joint replacement (TJR) that would allow for results from TJR studies to be compared or pooled. The Outcome Measures in Rheumatology (OMERACT) TJR core domain set is already endorsed among patients and physicians in the USA and Australia. Physiotherapists use different types of measurements compared to orthopaedic surgeons while both make substantial contributions to research in the field of TJR. To achieve consensus on core measurements sets, patients, physiotherapists and orthopaedic surgeons need to achieve consensus on the core domains for TJR trials. METHODS AND ANALYSIS For this multistage study, first, the OMERACT TJR core domain set survey will be translated to German and validated according to WHO guidelines. Next, the TJR core domain set will be considered for endorsement in different German stakeholder groups including patients, physiotherapists and orthopaedic surgeons. ETHICS AND DISSEMINATION Ethical approval for this protocol was given by the ethics committee of the Brandenburg University of Technology Cottbus-Senftenberg (BTU-CS, EK 2019-2). This article is based on the protocol version 2.5 from 6 May 2020. Anonymous data will be presented only. We will publish the results in peer-reviewed publications and at international conferences. TRIAL REGISTRATION NUMBER German Clinical Trials Registry (DRKS00016015).
Collapse
Affiliation(s)
- Robert Prill
- Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany
| | - Jasvinder A Singh
- Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA
- Medicine Service, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA
| | - Gesine H Seeber
- University Hospital of Orthopedics and Trauma Surgery Pius-Hospital, Medical Campus University Oldenburg, Oldenburg, Germany
| | - Sabrina Mai Nielsen
- Musculoskeletal Statistics Unit, The Parker Institute, Frederiksberg, Denmark
| | - Susan Goodman
- Integrative Rheumatology and Orthopedics Center of Excellence, Weill Cornell Medicine, Hospital for Special Surgery, New York, New York, USA
| | - Sven Michel
- Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany
| | - Christian Kopkow
- Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany
| | - Robert Schulz
- Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany
| | - Peter Choong
- Department of Surgery, St. Vincent's Hospital Melbourne, The University of Melbourne, Melbourne, Victoria, Australia
| | - Hagen Hommel
- Klinik für Orthopädie, Sportmedizin und Rehabilitation, Krankenhaus Markisch-Oderland GmbH, Wriezen, Germany
| |
Collapse
|
29
|
Festag J, Thelemann T, Schell M, Raith S, Michel S, Jaschinski F, Klar R. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation. Mol Ther Nucleic Acids 2020; 21:656-669. [PMID: 32739778 PMCID: PMC7393471 DOI: 10.1016/j.omtn.2020.06.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 06/12/2020] [Accepted: 06/23/2020] [Indexed: 01/09/2023]
Abstract
The adenosine axis contributes to the suppression of antitumor immune responses. The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73. Adenosine binds to, e.g., the A2a receptor (A2aR), which reportedly suppresses effector immune cells. We investigated effects of ATP, AMP, and adenosine analogs on T cell proliferation, apoptosis, and proinflammatory cytokine secretion. CD39 and CD73 expression were suppressed using antisense oligonucleotides (ASOs), and A2aR was blocked using small molecules. Addition of ATP to T cells reduced proliferation and induced apoptosis. Intriguingly, those effects were reverted by suppression of CD39 and/or CD73 expression but not A2aR inhibition. Adenosine analogs did not suppress proliferation but inhibited secretion of proinflammatory cytokines. Here, we suggest that suppression of T cell proliferation is not directly mediated by A2aR but by intracellular downstream metabolites of adenosine, as blockade of the equilibrative nucleoside transporter (ENT) or adenosine kinase rescued proliferation and prevented induction of apoptosis. In conclusion, adenosine might primarily affect cytokine secretion directly via adenosine receptors, whereas adenosine metabolites might impair T cell proliferation and induce apoptosis. Therefore, inhibition of CD39 and/or CD73 has evident advantages over A2aR blockade to fully revert suppression of antitumor immune responses by the adenosine axis.
Collapse
Affiliation(s)
- Julia Festag
- Secarna Pharmaceuticals GmbH & Co. KG, 82152 Planegg/Martinsried, Germany
| | - Tamara Thelemann
- Secarna Pharmaceuticals GmbH & Co. KG, 82152 Planegg/Martinsried, Germany
| | - Monika Schell
- Secarna Pharmaceuticals GmbH & Co. KG, 82152 Planegg/Martinsried, Germany
| | - Stefanie Raith
- Secarna Pharmaceuticals GmbH & Co. KG, 82152 Planegg/Martinsried, Germany
| | - Sven Michel
- Secarna Pharmaceuticals GmbH & Co. KG, 82152 Planegg/Martinsried, Germany
| | - Frank Jaschinski
- Secarna Pharmaceuticals GmbH & Co. KG, 82152 Planegg/Martinsried, Germany
| | - Richard Klar
- Secarna Pharmaceuticals GmbH & Co. KG, 82152 Planegg/Martinsried, Germany.
| |
Collapse
|
30
|
Aalbers BL, Hofland RW, Bronsveld I, de Winter-de Groot KM, Arets HGM, de Kiviet AC, van Oirschot-van de Ven MMM, Kruijswijk MA, Schotman S, Michel S, van der Ent CK, Heijerman HGM. Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males. J Cyst Fibros 2020; 20:e7-e11. [PMID: 32448708 DOI: 10.1016/j.jcf.2020.05.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 05/05/2020] [Accepted: 05/06/2020] [Indexed: 11/19/2022]
Abstract
AIM To explore which patient-related factors influence sweat test response to CFTR modulators, as well as examining the correlation between the sweat chloride response and ppFEV1 or BMI response, using systematically collected real-life clinical data. METHODS 160 CF patients were identified who had used lumacaftor/ivacaftor for at least six months. Of these patients, age, sweat chloride levels, ppFEV1 weight and BMI at the start of treatment and after 6 months were collected retrospectively. Pearson and Spearman tests were performed to assess correlations. RESULTS Females compared to males in this group showed a larger response in sweat chloride (mean difference 10.6 mmol/l, 95% CI: 5.7-15.4) and BMI (mean difference 0.27 kg/m2, 95% CI: 0.01-0.54). A modest but significant correlation was found between patient weight and sweat chloride response (Pearson R = 0.244, p = 0.001), which diminished upon correction for the other factors. The correlation between sex and sweat chloride response remained; R = 0.253, p = 0.001. Sweat chloride response did not correlate with ppFEV1 change or BMI change at 6 months after start of therapy. CONCLUSION Sweat chloride response is larger in females compared to males, which also explains the negative correlation of weight with the response in sweat chloride concentration after start of lumacaftor/ivacaftor. Sweat chloride response does not correlate with the responses in ppFEV1 and BMI. This information may help the interpretation of sweat test results acquired for the follow up and evaluation of CFTR modulating treatments, and warrants further investigation into the underlying mechanisms of sex differences in response to CFTR modulators.
Collapse
Affiliation(s)
- B L Aalbers
- Department of Pulmonology, University Medical Center Utrecht, the Netherlands.
| | - R W Hofland
- Department of Pulmonology, University Medical Center Utrecht, the Netherlands
| | - I Bronsveld
- Department of Pulmonology, University Medical Center Utrecht, the Netherlands
| | - K M de Winter-de Groot
- Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, Utrecht, the Netherlands
| | - H G M Arets
- Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, Utrecht, the Netherlands
| | - A C de Kiviet
- Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, Utrecht, the Netherlands
| | | | - M A Kruijswijk
- Department of Pulmonology, University Medical Center Utrecht, the Netherlands
| | - S Schotman
- Department of Pulmonology, University Medical Center Utrecht, the Netherlands
| | - S Michel
- Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, Utrecht, the Netherlands
| | - C K van der Ent
- Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, Utrecht, the Netherlands
| | - H G M Heijerman
- Department of Pulmonology, University Medical Center Utrecht, the Netherlands
| |
Collapse
|
31
|
Liu H, Zistler K, Jeridi A, Morrone C, Schulte-Döinghaus S, Hagl C, Yildirim A, Michel S, Dashkevich A. Rapid Activation of Pro-Lymphangiogenic Phenotype and Consequent Increase of Lymphatic Density Occurs during the Development of Chronic Lung Allograft Dysfunction. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
32
|
Traversier M, Gaslonde T, Lecso M, Michel S, Delannay E. Comparison of extraction methods for chemical composition, antibacterial, depigmenting and antioxidant activities of
Eryngium maritimum. Int J Cosmet Sci 2020; 42:127-135. [DOI: 10.1111/ics.12595] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Accepted: 11/20/2019] [Indexed: 01/03/2023]
Affiliation(s)
- M. Traversier
- Laboratoires Clarins 5 rue Ampère 95300 Pontoise France
- Laboratoire de Pharmacognosie UMR CNRS 8038 CiTCoM Université de Paris 75006 Paris France
| | - T. Gaslonde
- Laboratoire de Pharmacognosie UMR CNRS 8038 CiTCoM Université de Paris 75006 Paris France
| | - M. Lecso
- Laboratoire Ecosystème Intestinal Probiotiques Antibiotiques‐EA 4065 Université de Paris 75006 Paris France
| | - S. Michel
- Laboratoire de Pharmacognosie UMR CNRS 8038 CiTCoM Université de Paris 75006 Paris France
| | - E. Delannay
- Laboratoires Clarins 5 rue Ampère 95300 Pontoise France
| |
Collapse
|
33
|
Brenner P, Reichart B, Laengin M, Michel S, Buchholz S, Dashkevich A, Wolf E, Reimann K, Ayares D, Hagl C, Steen S, Abicht J. Worldwide First Successful and Reproducable Long-Term Survival up to Half a Year: Completed Preclinical Study with Life-Supporting Orthotopic Pig-to-Baboon Cardiac Xenotransplantation (oXHTx) Fullfilling the ISHLT Prerequisite for Clinical Cardiac Xenotransplantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
34
|
Bachmann M, Kuhnitzsch C, Thierbach A, Michel S, Bochnia M, Greef J, Martens S, Steinhöfel O, Zeyner A. Effects of toasting temperature and duration on in vitro ruminal gas production kinetics and post-ruminal crude protein from field pea (Pisum sativum) legume grain silages. Livest Sci 2020. [DOI: 10.1016/j.livsci.2020.103944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
35
|
Buchholz S, Rosenthal LL, Von Samson-Himmelstjerna P, Haas N, Hörer J, Hagl C, Michel S. Bridging Patients in Cardiogenic Shock with the Berlin Heart Excor Biventricular Assist Device to Heart Transplantation: A Single-Center Experience. Thorac Cardiovasc Surg 2020. [DOI: 10.1055/s-0040-1705495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
36
|
Brenner P, Reichart B, Längin M, Mayr T, Buchholz S, Michel S, Wolf E, Hagl C, Steen S, Abicht JM. Completed Preclinical Life-Supporting Orthotopic Pig-to-baboon Cardiac Xenotransplantation Study (oXHTx): First Successful and Reproducible Long-Term Survival Up to Half a Year Fulfilling the ISHLT Prerequisite for Clinical Cardiac Xenotransplantation. Thorac Cardiovasc Surg 2020. [DOI: 10.1055/s-0040-1705445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
37
|
Klar R, Michel S, Schell M, Hinterwimmer L, Zippelius A, Jaschinski F. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. Cancer Immunol Immunother 2019; 69:57-67. [PMID: 31802183 DOI: 10.1007/s00262-019-02438-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Accepted: 11/27/2019] [Indexed: 12/11/2022]
Abstract
Tumors can utilize a diverse repertoire of immunosuppressive mechanisms to evade attack by the immune system. Despite promising success with blockade of immune checkpoints like PD-1 the majority of patients does not respond to current immunotherapies. The degradation of tryptophan into immunosuppressive kynurenine is an important immunosuppressive pathway. Recent attempts to target the key enzymes of this pathway-IDO1 and TDO2-have so far failed to show therapeutic benefit in the clinic, potentially caused by insufficient target engagement. We, therefore, sought to add an alternative, highly efficient approach to block the degradation of tryptophan by inhibiting the expression of IDO1 and TDO2 using locked nucleic acid (LNA)-modified antisense oligonucleotides (ASOs). We show that LNA-modified ASOs can profoundly inhibit the expression of IDO1 and TDO2 in cancer cells in vitro without using a transfection reagent with IC50 values in the sub-micromolar range. We furthermore measured kynurenine production by ASO-treated cancer cells in vitro and observed potently reduced kynurenine levels. Accordingly, inhibiting IDO1 expression in cancer cells in an in vitro system leads to increased proliferation of activated T cells in coculture. We furthermore show that combined treatment of cancer cells in vitro with IDO1-specific ASOs and small molecule inhibitors can reduce the production of kynurenine by cancer cells in a synergistic manner. In conclusion, we propose that a combination of LNA-modified ASOs and small molecule inhibitors should be considered as a strategy for efficient blockade of the degradation of tryptophan into kynurenine in cancer immunotherapy.
Collapse
Affiliation(s)
- Richard Klar
- Secarna Pharmaceuticals GmbH & Co. KG, Am Klopferspitz 19, 82152, Planegg, Germany.
| | - Sven Michel
- Secarna Pharmaceuticals GmbH & Co. KG, Am Klopferspitz 19, 82152, Planegg, Germany
| | - Monika Schell
- Secarna Pharmaceuticals GmbH & Co. KG, Am Klopferspitz 19, 82152, Planegg, Germany
| | - Lisa Hinterwimmer
- Secarna Pharmaceuticals GmbH & Co. KG, Am Klopferspitz 19, 82152, Planegg, Germany
| | - Alfred Zippelius
- Cancer Immunology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.,Medical Oncology, University Hospital Basel, Basel, Switzerland
| | - Frank Jaschinski
- Secarna Pharmaceuticals GmbH & Co. KG, Am Klopferspitz 19, 82152, Planegg, Germany.
| |
Collapse
|
38
|
Wienbergen H, Retzlaff T, Erdmann J, Michel S, Mata Marin LA, Wettwer T, Schmucker J, Osteresch R, Munz M, Fach A, Hambrecht R. P6214How to improve long-term prevention in young patients after myocardial infarction - the IPP-Y study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Patients who experienced myocardial infarction (MI) at a young age are of special medical and socioeconomic interest; cardiovascular risk factor control to prevent recurrent events is crucial in this specific cohort.
Objectives
The purpose of the study was to evaluate long-term risk factor control in young MI-patients in clinical practice and investigate the effects of a modern intensive prevention program in a prospective randomized trial. In a genetic substudy it was analyzed if prevention effects were depending on individual genetic risk.
Methods
Patients who had MI at age of ≤45 years were revisited after a mean period of 5.7±4.0 years to evaluate long-term risk factor control. Furthermore a 12-months intensive prevention program in young MI-patients (IPP-Y), coordinated by non-physician prevention assistants and including personal teachings, telephone contacts, clinical and telemetric control of risk factors, was compared to usual care in a randomized trial. Primary endpoint of the randomized trial was prevention success, defined as improvement of one of the risk factors smoking, LDL cholesterol or physical inactivity without deterioration of the others. As the opposite prevention failure was defined as deterioration of one of the risk factors without improvement of the others. Genetic risk was assessed by polygenetic risk scores, based on 163 SNPs.
Results
Only a minority of the 277 young patients after MI achieved guideline-recommended risk factor targets at long-term follow-up visits: mean body mass index was 29.9±5.1 kg/m2, just 14.8% had a body mass index <25 kg/m2. More than one third (38.3%) were persistent or recurrent smokers. Mean LDL cholesterol level was 94±38 mg/dl, only 27.1% of the patients achieved LDL cholesterol levels <70 mg/dl.
However, the long-term prevention program IPP-Y led to a higher rate of the primary endpoint prevention success (IPP-Y: 49% vs. UC: 27%, p<0.05) and a lower rate of prevention failure (IPP-Y: 15% vs. UC: 38%, p<0.05) compared to usual care after 12 months (see figure). Telemetric control of risk factors as part of the prevention program was used by 71.4% of the patients.
In the genetic subanalysis prevention effects were found in both, patients with high genetic risk as well as patients with low genetic risk assessed by polygenetic risk scores (p=0.79 high vs. low genetic risk).
Effects of IPP-Y during 12 months
Conclusions
To our knowledge this is the first study on young patients with MI that demonstrates insufficient long-term risk factor control in clinical practice and significant effects of an intensive prevention program. Prevention effects were independent from individual genetic risk.
Acknowledgement/Funding
This work was supported by the Stiftung Bremer Herzen, Bremen, Germany and the Stiftung Bremer Wertpapierbörse, Bremen, Germany
Collapse
Affiliation(s)
- H Wienbergen
- Bremen Institute for Heart and Circulation Research, Klinikum Links der Weser, Bremen, Germany
| | - T Retzlaff
- Bremen Institute for Heart and Circulation Research, Klinikum Links der Weser, Bremen, Germany
| | - J Erdmann
- Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany
| | - S Michel
- Bremen Institute for Heart and Circulation Research, Klinikum Links der Weser, Bremen, Germany
| | - L A Mata Marin
- Bremen Institute for Heart and Circulation Research, Klinikum Links der Weser, Bremen, Germany
| | - T Wettwer
- Bremen Institute for Heart and Circulation Research, Klinikum Links der Weser, Bremen, Germany
| | - J Schmucker
- Bremen Institute for Heart and Circulation Research, Klinikum Links der Weser, Bremen, Germany
| | - R Osteresch
- Bremen Institute for Heart and Circulation Research, Klinikum Links der Weser, Bremen, Germany
| | - M Munz
- Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany
| | - A Fach
- Bremen Institute for Heart and Circulation Research, Klinikum Links der Weser, Bremen, Germany
| | - R Hambrecht
- Bremen Institute for Heart and Circulation Research, Klinikum Links der Weser, Bremen, Germany
| |
Collapse
|
39
|
Schmucker J, Fach A, Osteresch R, Retzlaff T, Michel S, Garstka D, Wettwer T, Hambrecht R, Wienbergen H. P2660Definition of clinically relevant thresholds of acute kidney injury in patients with ST-elevation myocardial infarctions undergoing primary percutaneous coronary interventions. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Although the clinical importance of deteriorating kidney function in patients with ST-elevation-myocardial infarctions (STEMI) on overall prognosis is generally accepted, there is conflicting evidence on the importance of small changes in renal function. Aim of the present study was to calculate clincially relevant thresholds for deterioration of renal function after STEMI.
Methods
From a large registry of patients with STEMI renal function was estimated calculating the glomerular filtration rate (GFR in ml/min/1.73 m2) with the CKD-EPI-equation. To assess acute kidney injury the ratio GFR (at peak creatinine))/ GFR (at admission) was calculated for each patient (with 1 representing no change). Patients were graded by GFR-reduction and assigned to 11 groups (G1 to G11) each representing 5% intervals.
Results
Of 6583 patients admitted with STEMI between 2006–2017 3518 (53%) had no change or a change <5% during hospital stay (G1) while 161 (3%) showed a decrease in GFR of ≥50% (G11). The rest of the patients could be attributed to G2- G10 (table). There was a pronounced correlation between extent of GFR-reduction and peak creatine kinase (indicating size of STEMI, r2=0.785; G1: 1521±1684 U/l vs. G11: 2885±2943 U/l, p<0.01) as well as left-ventricular ejection fraction (LVEF) (r2=0.79; G1: 50.9±9% vs. G11: 41.4±10%, p<0.01). However, no such correlation could be detected between GFR-reduction and amount of contrast media (CM) applied (r2=0.05, G1: 141±60 ml vs. G11: 139±61 ml, p=0.5). Analysis of outcome-data (1-year-mortality and major adverse cardiovascular and cerebrovascular events (MACCE: death, stroke, re-infarction)) revealed, that beneath a threshold of 25% deterioration of renal function did not significantly impact prognosis, while higher degrees of deterioration led to a 7-fold increase in mortality and a 5-fold increase in MACCE-rates (table).
Impact of GFR-reduction on outcome Group G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 GFR-reduction (in %) 0–4 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 ≥50 Patients, n (%) 3518 (53) 881 (13) 717 (11) 492 (7) 327 (5) 196 (3) 119 (2) 88 (1) 48 (1) 36 (1) 161 (3) 1 year mortality (%) 7 4 5 8 7 15 20 22 39 43 50 1-year-MACCE (%) 12 8 8 12 10 19 27 27 49 49 52
Conclusions
These data from a large STEMI-registry show that small changes (less than 25%) in GFR did not significantly impact long-term outcome, while the impact was pronounced for all patients beyond that threshold. The degree of renal deterioration furthermore correlated with size of STEMI as well as reduction of LV-function after STEMI while no correlation to amount of contrast media could be found.
Collapse
Affiliation(s)
- J Schmucker
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - A Fach
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - R Osteresch
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - T Retzlaff
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - S Michel
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - D Garstka
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - T Wettwer
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - R Hambrecht
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - H Wienbergen
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| |
Collapse
|
40
|
Schmucker J, Fach A, Osteresch R, Retzlaff T, Michel S, Garstka D, Wienbergen H, Hambrecht R. 465Benefit of modern P2Y12-inhibitors on long-term prognosis in patients with ST-elevation myocardial infarction with and without advanced chronic kidney disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Current guidelines on the management of patients with ST-elevation myocardial infarction (STEMI) recommend the preferred use of the modern P2Y12-inhibitors ticagrelor or prasugrel regardless of the presence of chronic kidney disease (CKD), although patients with advanced stages of CKD were excluded from randomized trials. Aim of the present study was therefore to evaluate the potential benefit of modern P2Y12-inhibitors in patients with and without advanced renal disease at admission.
Methods
All patients admitted with STEMI between 2006–2017 from a large german heart center treated with primary percutaneous coronary intervention (PCI) entered analysis. Initial CKD was estimated with the initial glomerular filtration rate (GFR), calculated with the CKD-EPI-equation, assigning them to the groups G1-G5.
Results
Of 7227 patients with STEMI and primary PCI 2669 (37%) showed no relevant reduction in GFR at admission (≥90 ml/min/1.73 m2, G1), 2976 pts. (41%), a slight reduction (GFR 60–89 ml/min/1.73 m2, G2), 880 pts. (12%) a moderate reduction (GFR 45–59 ml/min/1.73 m2, G3a) and 702 pts. (10%) a moderate to severe reduction (GFR<45 ml/min 1.73 m2, G3b-G5). Pts. with more advanced stages of CKD were on average older (G1: 55±11 years, G2: 66±12 years, G3a: 72±12 years, G3b-G5: 75±11 years, p<0.01) and more likely to be female (G1: 19%, G2: 26%, G3a: 40%, G3b-G5: 48%, p<0.01). Prasugrel/ticagrelor were less often given instead of clopidogrel in patients with advanced CKD (G1: 70%, G2: 45%, G3a: 31%, G3b-G5: 32%, p<0.01). The use of ticagrelor/prasugrel was associated with a reduction in 1-year-MACCE (major adverse cardio- and cerebrovascular events)-rates in patients with no/low-grade-CKD (G1-G2), while no significant reduction in MACCE could be observed for patients with moderate to severe CKD (table). Furthermore, CKD was associated with an elevation in severe bleeding events within 1 year (G1: 1%, G2: 3%, G3a: 5%, G3b-G5: 6%, p<0.01).
Impact of CKD-stage on outcome CKD-stage G1 CKD-stage G2 CKD-stage G3a CKD-stage G3b-G5 1-year-MACCE-rate (%) Ticagrelor/prasugrel 4.5 11.0 27.4 47.3 Clopidogrel 9.9 15.6 26.6 50.4 Significance <0.01 <0.01 0.6 0.7
Conclusions
These data from a large STEMI-registry demonstrate, that modern P2Y12-inhibitors were less often used in patients with CKD and their benefit regarding MACCE disappeared in advanced stages of CKD while bleeding rates increased. These results underline the special role of patients with advanced stage-CKD in STEMI and the necessity of specialized randomized trials for these patients.
Collapse
Affiliation(s)
- J Schmucker
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - A Fach
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - R Osteresch
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - T Retzlaff
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - S Michel
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - D Garstka
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - H Wienbergen
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| | - R Hambrecht
- Hospital Links der Weser, Institut fuer Herz- und Kreislaufforschung, Bremen, Germany
| |
Collapse
|
41
|
Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC. Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nat Commun 2019; 10:3680. [PMID: 31417079 PMCID: PMC6695448 DOI: 10.1038/s41467-019-11563-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Yu Cao
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Jimena Trillo-Tinoco
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Rosa A Sierra
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Carmen Anadon
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Wenjie Dai
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Eslam Mohamed
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Ling Cen
- Cancer Informatics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Tara L Costich
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Anthony Magliocco
- Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Douglas Marchion
- Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Richard Klar
- Secarna Pharmaceuticals GmbH & Co. KG, 82152, Planegg/Martinsried, Germany
| | - Sven Michel
- Secarna Pharmaceuticals GmbH & Co. KG, 82152, Planegg/Martinsried, Germany
| | - Frank Jaschinski
- Secarna Pharmaceuticals GmbH & Co. KG, 82152, Planegg/Martinsried, Germany
| | - Richard R Reich
- Biostatistics Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Shikhar Mehrotra
- Department of Surgery, Medical University of South Carolina, Charleston, SC, 29425, USA
| | - Juan R Cubillos-Ruiz
- Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, 10065, USA.,Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, 10065, USA
| | - David H Munn
- Department of Pediatrics, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA
| | - Jose R Conejo-Garcia
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Paulo C Rodriguez
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA.
| |
Collapse
|
42
|
Riordan E, Blomgren J, Jonasson C, Ahrentorp F, Johansson C, Margineda D, Elfassi A, Michel S, Dell'ova F, Klemencic GM, Giblin SR. Design and implementation of a low temperature, inductance based high frequency alternating current susceptometer. Rev Sci Instrum 2019; 90:073908. [PMID: 31370440 DOI: 10.1063/1.5074154] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Accepted: 07/09/2019] [Indexed: 06/10/2023]
Abstract
We report on the implementation of an induction based, low temperature, high frequency ac susceptometer capable of measuring at frequencies up to 3.5 MHz and at temperatures between 2 K and 300 K. Careful balancing of the detection coils and calibration allow a sample magnetic moment resolution of 5 × 10-10 Am2 at 1 MHz. We discuss the design and characterization of the susceptometer and explain the calibration process. We also include some example measurements on the spin ice material CdEr2S4 and iron oxide based nanoparticles to illustrate functionality.
Collapse
Affiliation(s)
- E Riordan
- Department of Physics & Astronomy, Cardiff University, Cardiff CF24 3AA, United Kingdom
| | - J Blomgren
- RISE Acreo, Arvid Hedvalls Backe 4, Box 53071, SE-400 14 Göteborg, Sweden
| | - C Jonasson
- RISE Acreo, Arvid Hedvalls Backe 4, Box 53071, SE-400 14 Göteborg, Sweden
| | - F Ahrentorp
- RISE Acreo, Arvid Hedvalls Backe 4, Box 53071, SE-400 14 Göteborg, Sweden
| | - C Johansson
- RISE Acreo, Arvid Hedvalls Backe 4, Box 53071, SE-400 14 Göteborg, Sweden
| | - D Margineda
- Department of Physics & Astronomy, Cardiff University, Cardiff CF24 3AA, United Kingdom
| | - A Elfassi
- INSA, Institut National des Sciences Appliques, Toulouse, 135 Avenue de Rangueil, 31077 Toulouse Cedex 4, France
| | - S Michel
- INSA, Institut National des Sciences Appliques, Toulouse, 135 Avenue de Rangueil, 31077 Toulouse Cedex 4, France
| | - F Dell'ova
- INSA, Institut National des Sciences Appliques, Toulouse, 135 Avenue de Rangueil, 31077 Toulouse Cedex 4, France
| | - G M Klemencic
- Department of Physics & Astronomy, Cardiff University, Cardiff CF24 3AA, United Kingdom
| | - S R Giblin
- Department of Physics & Astronomy, Cardiff University, Cardiff CF24 3AA, United Kingdom
| |
Collapse
|
43
|
Klar R, Cao Y, Mohamed E, Michel S, Schell M, Hinterwimmer L, Raith S, Rodriguez P, Jaschinski F. Abstract 3275: Inhibition of ER-stress factor C/EBP homologous protein (Chop) with LNAplus™ antisense-oligonucleotides to improve immunotherapy of cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The microenvironment generated by tumor cells and suppressive stromal cells creates unfavorable conditions for effector immune cells in order to escape anti-tumor immunity. Besides suppressive pathways like for example the CD39/CD73 axis, mechanisms including nutrient starvation, hypoxia, exposure to high levels of reactive oxygen species and acidosis contribute to the suppression of tumor-reactive immune cells. We have recently discovered that the ER-stress response, in particular the C/EBP homologous protein (Chop) plays an important role in the suppression of tumor-exposed T cells. Furthermore, it is upregulated in activated T cells in vitro and may hamper the efficacy of adoptive T cell therapies. As Chop is a transcription factor it falls into the category of “difficult to drug” and therefore represents an optimal target for antisense-oligonucleotides. In order to revert Chop-induced suppression of T cell activity, we designed locked nucleic acid (LNA) ASOs with specificity for mouse or human Chop using our Oligofyer™ bioinformatics system. Knockdown on mRNA level was investigated in cancer cell lines and in T cells in vitro and the most potent ASOs were selected for further experiments. Downstream effects of Chop knockdown were investigated by mRNA expression analysis and flow cytometry. We furthermore investigated the effect of ex vivo Chop knockdown on the efficacy of adoptively transferred Pmel-specific T cells (recognized target: gp10025-33 peptide) in a B16 melanoma model. Treatment of cells with selected Chop-specific ASO leads to potent knockdown of Chop in vitro. In accordance with observations made in T cells derived from Chop-knockout mice, we observed an increase in T cell-associated transcription factor (Tbet), Interferon-gamma (IFN-γ) and Granzyme B (GZMB) expression in T cells that have been treated with a Chop ASO compared to control oligo treated cells. Strikingly, this translated into improved tumor control by Pmel-specific T cells. We furthermore observed an increase in IFN-γ producing tumor-infiltrating T cells and increased frequency of IFN-γ producing T cells in gp100 restimulated splenocytes from animals that received Chop ASO-treated Pmel-specific T cells. Of note, the impact of Chop knockdown was comparable to the effects that we observed in T cells derived from Chop knockout animals. Taken together, we herein show that Chop is a highly promising novel target in immunotherapy and can effectively be targeted by LNAplus™ ASOs. As shown in a model of adoptive T cell therapy, Chop ASOs have a high potential to optimize the efficacy of T cell therapies, such as chimeric antigen receptor (CAR)- or T cell receptor (TCR)-transgenic T cells. We are currently investigating the effect of systemic Chop ASO treatment in murine tumor models to expand the spectrum of applications of this innovative therapeutic tool.
Citation Format: Richard Klar, Yu Cao, Eslam Mohamed, Sven Michel, Monika Schell, Lisa Hinterwimmer, Stefanie Raith, Paulo Rodriguez, Frank Jaschinski. Inhibition of ER-stress factor C/EBP homologous protein (Chop) with LNAplus™ antisense-oligonucleotides to improve immunotherapy of cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3275.
Collapse
Affiliation(s)
- Richard Klar
- 1Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
| | - Yu Cao
- 2H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Eslam Mohamed
- 2H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Sven Michel
- 1Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
| | - Monika Schell
- 1Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
| | | | - Stefanie Raith
- 1Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
| | - Paulo Rodriguez
- 2H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | | |
Collapse
|
44
|
Gaertner VD, Michel S, Curtin JA, Pulkkinen V, Acevedo N, Söderhäll C, von Berg A, Bufe A, Laub O, Rietschel E, Heinzmann A, Simma B, Vogelberg C, Pershagen G, Melén E, Simpson A, Custovic A, Kere J, Kabesch M. Nocturnal asthma is affected by genetic interactions between RORA and NPSR1. Pediatr Pulmonol 2019; 54:847-857. [PMID: 30927345 DOI: 10.1002/ppul.24292] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2018] [Revised: 12/17/2018] [Accepted: 02/04/2019] [Indexed: 12/11/2022]
Abstract
BACKGROUND Neuropeptide S Receptor 1 ( NPSR1) and Retinoid Acid Receptor-Related Orphan Receptor Alpha (RORA ) interact biologically, are both known candidate genes for asthma, and are involved in controlling circadian rhythm. Thus, we assessed (1) whether interactions between RORA and NPSR1 specifically affect the nocturnal asthma phenotype and (2) how this may differ from other asthma phenotypes. METHODS Interaction effects between 24 single-nucleotide polymorphisms (SNPs) in RORA and 35 SNPs in NPSR1 on asthma and nocturnal asthma symptoms were determined in 1432 subjects (763 asthmatics [192 with nocturnal asthma symptoms]; 669 controls) from the Multicenter Asthma Genetic in Childhood/International Study of Asthma and Allergies in Childhood studies. The results were validated and extended in children from the Manchester Asthma and Allergy Study (N = 723) and the Children Allergy Milieu Stockholm and Epidemiological cohort (N = 1646). RESULTS RORA* NPSR1 interactions seemed to affect both asthma and nocturnal asthma. In stratified analyses, however, interactions mainly affected nocturnal asthma and less so asthma without nocturnal symptoms or asthma severity. Results were replicated in two independent cohorts and seemed to remain constant over time throughout youth. CONCLUSION RORA* NPSR1 interactions appear to be involved in mechanisms specific for nocturnal asthma. In contrast to previous studies focusing on the role of beta 2 receptor polymorphisms in nocturnal asthma as a feature of asthma control or severity in general, our data suggest that changes in circadian rhythm control are associated with nighttime asthma symptoms.
Collapse
Affiliation(s)
- Vincent D Gaertner
- Department of Pediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO), Regensburg, Germany
| | - Sven Michel
- Department of Pediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO), Regensburg, Germany
| | - John A Curtin
- Division of Infection Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester Academic Health Science Centre, and Manchester University NHS Foundation Trust, Manchester, UK
| | - Ville Pulkkinen
- Heart and Lung Center, Division of Pulmonary Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - Nathalie Acevedo
- Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden.,Institute for Immunological Research, University of Cartagena, Cartagena, Colombia
| | - Cilla Söderhäll
- Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.,Department of Women´s and Children's Health, Karolinska Institutet, Stockholm, Sweden
| | - Andrea von Berg
- Children's Department, Research Institute for the Prevention of Allergic Diseases, Marien-Hospital, Wesel, Germany
| | - Albrecht Bufe
- Department of Experimental Pneumology, Ruhr-University, Bochum, Germany
| | - Otto Laub
- Kinder- und Jugendarztpraxis Laub, Rosenheim, Germany
| | - Ernst Rietschel
- Faculty of Medicine, University Children's Hospital, University of Cologne, Cologne, Germany
| | - Andrea Heinzmann
- Center for Pediatrics, Department of General Pediatrics, Adolescent Medicine and Neonatology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg im Breisgau, Germany
| | - Burkhard Simma
- Children's Department, University Teaching Hospital, Landeskrankenhaus Feldkirch, Feldkirch, Austria
| | - Christian Vogelberg
- University Children's Hospital, Technical University Dresden, Dresden, Germany
| | - Göran Pershagen
- Institute of Environmental Medicine, Karolinska Institutet and Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden
| | - Erik Melén
- Institute of Environmental Medicine, Karolinska Institutet and Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden.,Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden
| | - Angela Simpson
- Division of Infection Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester Academic Health Science Centre, and Manchester University NHS Foundation Trust, Manchester, UK
| | | | - Juha Kere
- Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.,Research Programs Unit, Program for Molecular Neurology, University of Helsinki, Folkhälsän Institute of Genetics, Helsinki, Finland
| | - Michael Kabesch
- Department of Pediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO), Regensburg, Germany.,School of Basic & Medical Biosciences, King's College London, London, England
| |
Collapse
|
45
|
Aalbers B, de Winter-de Groot K, Arets H, Hofland R, de Kiviet A, van Oirschot-van de Ven M, Kruijswijk M, Schotman S, Michel S, van der Ent C, Heijerman H. P261 Clinical effect of lumacaftor/ivacaftor in F508del homozygous cystic fibrosis patients with FEV1 ≥90% predicted at baseline. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30554-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
46
|
Prill R, Schulz R, Michel S. Tissue flossing: a new short-term compression therapy for reducing exercise-induced delayed-onset muscle soreness. A randomized, controlled and double-blind pilot crossover trial. J Sports Med Phys Fitness 2019; 59:861-867. [DOI: 10.23736/s0022-4707.18.08701-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
47
|
Kashyap AS, Thelemann T, Klar R, Kallert SM, Festag J, Buchi M, Hinterwimmer L, Schell M, Michel S, Jaschinski F, Zippelius A. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity. J Immunother Cancer 2019; 7:67. [PMID: 30871609 PMCID: PMC6419472 DOI: 10.1186/s40425-019-0545-9] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 02/22/2019] [Indexed: 12/16/2022] Open
Abstract
Background Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP to adenosine. CD39 is expressed by different immune cell populations as well as cancer cells of different tumor types and supports the tumor in escaping immune recognition and destruction. Thus, increasing extracellular ATP and simultaneously reducing adenosine concentrations in the tumor can lead to effective anti-tumor immunity. Methods We designed locked nucleic acid (LNA)-modified antisense oligonucleotides (ASOs) with specificity for human or mouse CD39 that do not need a transfection reagent or delivery system for efficient target knockdown. Knockdown efficacy of ASOs on mRNA and protein level was investigated in cancer cell lines and in primary human T cells. The effect of CD39 knockdown on ATP-degrading activity was evaluated by measuring levels of ATP in tumor cell supernatants and analysis of T cell proliferation in the presence of extracellular ATP. The in vivo effects of CD39-specific ASOs on target expression, anti-tumor immune responses and on tumor growth were analyzed in syngeneic mouse tumor models using multi-color flow cytometry. Results CD39-specific ASOs suppressed expression of CD39 mRNA and protein in different murine and human cancer cell lines and in primary human T cells. Degradation of extracellular ATP was strongly reduced by CD39-specific ASOs. Strikingly, CD39 knockdown by ASOs was associated with improved CD8+ T cell proliferation. Treatment of tumor-bearing mice with CD39-specific ASOs led to dose-dependent reduction of CD39-protein expression in regulatory T cells (Tregs) and tumor-associated macrophages. Moreover, frequency of intratumoral Tregs was substantially reduced in CD39 ASO-treated mice. As a consequence, the ratio of CD8+ T cells to Tregs in tumors was improved, while PD-1 expression was induced in CD39 ASO-treated intratumoral CD8+ T cells. Consequently, CD39 ASO treatment demonstrated potent reduction in tumor growth in combination with anti-PD-1 treatment. Conclusion Targeting of CD39 by ASOs represents a promising state-of-the art therapeutic approach to improve immune responses against tumors. Electronic supplementary material The online version of this article (10.1186/s40425-019-0545-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Abhishek S Kashyap
- Cancer Immunology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland
| | | | - Richard Klar
- Secarna Pharmaceuticals GmbH, Planegg/Martinsried, Germany
| | - Sandra M Kallert
- Cancer Immunology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.,Present address: Novartis Institute of Biomedical Research, 4002, Basel, Switzerland
| | - Julia Festag
- Secarna Pharmaceuticals GmbH, Planegg/Martinsried, Germany
| | - Melanie Buchi
- Cancer Immunology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland
| | | | - Monika Schell
- Secarna Pharmaceuticals GmbH, Planegg/Martinsried, Germany
| | - Sven Michel
- Secarna Pharmaceuticals GmbH, Planegg/Martinsried, Germany
| | | | - Alfred Zippelius
- Cancer Immunology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland. .,Medical Oncology, University Hospital Basel, Basel, Switzerland.
| |
Collapse
|
48
|
Potaczek DP, Unger SD, Zhang N, Taka S, Michel S, Akdag N, Lan F, Helfer M, Hudemann C, Eickmann M, Skevaki C, Megremis S, Sadewasser A, Alhamwe BA, Alhamdan F, Akdis M, Edwards M, Johnston SL, Akdis CA, Becker S, Bachert C, Papadopoulos NG, Garn H, Renz HE. Development of antirhinoviral DNAzymes for effective prevention of asthma exacerbations. J Allergy Clin Immunol 2019. [DOI: 10.1016/j.jaci.2018.12.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Santi M, Bouzidi C, Gorod N, Puiatti M, Michel S, Grougnet R, Ortega M. In vitro biological evaluation and molecular docking studies of natural and semisynthetic flavones from Gardenia oudiepe (Rubiaceae) as tyrosinase inhibitors. Bioorg Chem 2019; 82:241-245. [DOI: 10.1016/j.bioorg.2018.10.034] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Revised: 10/13/2018] [Accepted: 10/17/2018] [Indexed: 02/01/2023]
|
50
|
Brenner P, Längin M, Mayr T, Güthoff S, Buchholz S, Michel S, Dashkevich A, Lutzmann I, Werner F, Klymiuk N, Wolf E, Reimann K, Hermanns W, Ayares D, Hagl C, Steen S, Abicht JM, Reichart B. Breakthrough in Orthotopic Cardiac Xenotransplantation: In a Preclinical Life-Supporting Pig-To-Baboon Model Worldwide First Continuous Successful Long-Term Survival (Up To 172/187 Days, Both Ongoing). Thorac Cardiovasc Surg 2019. [DOI: 10.1055/s-0039-1678915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- P. Brenner
- LMU München, Klinikum Grosshadern, Herzchirurgische Klinik, München, Germany
| | - M. Längin
- LMU Munich, Anaesthesiology, München, Germany
| | - T. Mayr
- LMU Munich, Walter-Brendel-Centre, München, Germany
| | - S. Güthoff
- LMU Munich, Walter-Brendel-Centre, München, Germany
| | - S. Buchholz
- LMU München, Klinikum Grosshadern, Herzchirurgische Klinik, München, Germany
| | - S. Michel
- LMU München, Klinikum Grosshadern, Herzchirurgische Klinik, München, Germany
| | - A. Dashkevich
- LMU München, Klinikum Grosshadern, Herzchirurgische Klinik, München, Germany
| | - I. Lutzmann
- LMU München, Walter-Brendel-Centre, München, Germany
| | - F. Werner
- LMU München, Walter-Brendel-Centre, München, Germany
| | - N. Klymiuk
- LMU München, Molecular Animal Breeding and Biotechnology, München, Germany
| | - E. Wolf
- LMU München, Molecular Animal Breeding and Biotechnology, München, Germany
| | - K. Reimann
- University of Massachusetts, Mass Biologics, Boston, United States
| | - W. Hermanns
- LMU München, Veterinary Pathology, München, Germany
| | - D. Ayares
- Revivicor Inc., Blackburn, United States
| | - C. Hagl
- LMU München, Klinikum Grosshadern, Herzchirurgische Klinik, München, Germany
| | - S. Steen
- University of Lund, Cardiothoracic Surgery, Lund, Sweden
| | | | - B. Reichart
- LMU Munich, Walter-Brendel-Centre, München, Germany
| |
Collapse
|